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Preeclampsia (PE) and HIV/AIDS contribute significantly to adverse maternal and perinatal outcomes 
globally. The treatment of PE remains empiric, however in HIV infection, highly active antiretroviral 
therapy (HAART) is used routinely for maternal health and the prevention of vertical transmission in 
pregnancy. The relationship between PE and HIV /HAART remains controversial and despite extensive 
research, the pathophysiology of both conditions is not fully understood. Contemporary and new 
research strategies include immunological and genetic aspects of PE and HIV, and clinical and 
biochemical effects associated with HAART.  
 
Aims and Objectives: 
The aims of the study were to determine: (1) the association of HIV and HAART with clinical and 
biochemical indices in women with PE, (2) the effects of HAART in relation to inflammatory cytokines 
in PE and HIV, and (3) the role of gene polymorphisms in preeclamptic women with HIV on HAART.   
The specific objectives of the study were to identify significant differences (p>0.05) in the routine 
clinical and laboratory indices between the preeclamptic groups, (2) to identify significant changes in 
pro-inflammatory cytokines IL2, TNFα, IFNɣ and IL6 in relation to HIV / HAART and preeclampsia, 
and (3) to determine the association of single nucleotide polymorphisms (SNP) miRNA 27a (rs 
895819T>C) and miRNA 146a ( rs 2910164G>C)  with preeclampsia risk and susceptibility to 
associated factors.   
 
Materials and Methods:  
A prospective cohort study was conducted between July 2013 and September 2014 at Prince Mshiyeni 
Memorial Hospital in Durban, South Africa. To maintain ethnographic and anthropometric consistency, 
a standard cohort of one hundred and ninety three (193) Black women of Zulu ethnicity comprising 4 
groups: i.e.  uninfected normotensive (50; 26%), infected normotensive (45; 23%), uninfected 
preeclamptic (53; 28%) and infected preeclamptic women (45; 23%) was recruited during pregnancy 
after ethical approval and informed consent and followed until delivery. Women with gestational 
hypertension, renal disease, diabetes mellitus, chronic hypertension and collagen vascular disease were 
excluded. Specific patient characteristics, clinical features, laboratory indices, and complications were 
analysed descriptively. Serum levels of pro-inflammatory cytokines TNF-α, IFN- γ, IL2 and IL6 were  




determined, using commercially available kits and Cytometric Bead Array (CBA). Genotyping using 
PCR and the TaqMan® SNP genotyping assay for  single nucleotide polymorphisms miRNA 27a 
rs895819T>C and miRNA 146a rs 2910164G>C was performed  and analysed in relation to 
preeclampsia risk, susceptibility to related clinical features and pro-inflammatory cytokines. 
Comparative data was recorded and analysed descriptively. 
 
Results: 
Our results indicate that the clinical features, laboratory indices, and complications among HIV infected 
preeclamptic women on HAART is similar to uninfected preeclamptic women. However, 
gammaglutamyl transferase (GGT), a hepatic enzyme, was markedly elevated (p=0.001) in HIV 
infected preeclamptic women on HAART. There were significant decreases in pro-inflammatory 
cytokines IL2 (p=0.010), TNF-α (p=0.045), and IL6 (p=0.005), in normotensive women on HAART 
compared with uninfected women and significant decreases in IL2 (p=0.000) and TNFα (p=0.000) in 
preeclamptic women on HAART compared with uninfected preeclamptic women. In the genotype 
analyses, we found that the variant genotypes (GC/CC)  in miRNA 146a were significantly associated 
with lower severe preeclampsia risk (OR: 0.34, 0.12-0.99; p=0.048), especially in the presence of 
HIV/HAART (OR: 0.11; 0.02-0.68, p= 0.018), and  the variant genotype (TC/CC)  in miRNA 27a was 
associated with  an elevated BMI in preeclamptic women (32.57 vs 29.25; p= 0.06), especially in the 
presence of HIV/HAART (33.47 vs 27.87; p=0.005).  
 
Conclusion:  
The effects of HIV and HAART influence biochemical, immunological and genetic aspects in women 
with preeclampsia.  Gammaglutamyl transferase, a hepatic enzyme, was markedly elevated and 
suggests a possible compounding effect on the liver, which is a target organ for preeclampsia and the 
side effects of HAART. Current management guidelines remain appropriate, however serial hepatic 
function tests are necessary in clinical practice.  The prevention of obesity is also necessary to reduce 
long term cardiovascular complications associated with these conditions. The immune reconstitutive 
effects of HAART include a reduction in pro-inflammatory cytokines in normotensive women as well 
as in preeclamptic women, which may have a bearing on the clinical course of preeclampsia in women 
on HAART. MiRNA 27a and miRNA 146a are endogenous small RNAs that post transcriptionally 
regulate gene expression and are implicated in a plethora of pathophysiological processes related to 




nucleotide polymorphisms (SNP) microRNA27a (rs 895819 T>C) and microRNA 146a (rs 
2910164G>C were   associated with obesity and severe preeclampsia respectively. Obesity is a well-
recognised risk factor for preeclampsia, and severe preeclampsia is associated with increased morbidity 
and mortality.  These findings demonstrate the importance of molecular genetics and inflammatory 

























Preeclampsia (PE) is a pregnancy specific syndrome accompanied by the de novo appearance of 
hypertension and significant proteinuria after mid-gestation (Katritsis, Gersh et al. 2013). It complicates 
2-10% of pregnancies and is associated with significant maternal and neonatal morbidity and mortality 
(Backes, Markham et al. 2011). HIV/AIDS is caused by infection with the human immunodeficiency 
virus (HIV) and accounts for approximately 5 % of pregnancy related deaths worldwide and 25% in 
Sub-Saharan Africa (Calvert and Ronsmans 2013). 
 
HIV, a ribonucleic acid (RNA) retrovirus, is associated with infection of the host immune cells 
particularly CD4+ T lymphocytes, (Williams and Hopper 2015), and can lead to the acquired immune 
deficiency syndrome (AIDS), if left untreated (Fauci 2003). Highly active antiretroviral therapy 
(HAART) has been shown to successfully reduce plasma HIV-1 viral load and vertical transmission 
rates in pregnancy (Autran, Carcelain et al. 1997), (Siegfried, van der Merwe et al. 2011) and is now 
incorporated into routine policy guidelines (Southern African 2013). 
 
The pathophysiology of PE (PE) remains unknown and treatment remains empiric. Current theories 
include inter alia, an abnormal maternal inflammatory response, deranged immunity and endothelial 
cell damage with a deranged hemodynamic milieu (Eiland, Nzerue et al. 2012). Recently, epigenetic 
factors and single nucleotide polymorphisms (SNPs) have also been suggested in the pathophysiology 
of PE (Magee, Pels et al. 2014).  
 
It is evident however, that inflammation is a common thread in the pathophysiology of both conditions 
(Deeks 2011, Catarino, Santos-Silva et al. 2012), and is mediated by a variety of soluble factors, 
including cytokines (Shaikh, Sharma et al. 2011). In PE , the release of pro-inflammatory cytokines 
may trigger the maternal disease (Sargent, Borzychowski et al. 2006). In the progression of HIV 
infection, a pro-inflammatory to eosinophilic/anti-inflammatory cytokine shift has been observed, 
which appears to be counteracted with the usage of HAART  (Fiore, Newell et al. 2006). 
 
Regarding epigenetic factors and inflammation, microRNAs (miRNAs), small non–coding RNA 
molecules, such as  miRNA-146a (miR-146a), has been noted to play a critical role in immune 
responses, viral infection and inflammatory disease (Hill, Clement et al. 2015), by preventing 
overstimulation of the inflammatory response through its recognised target genes, interleukin-1 receptor 
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associated kinase 1 (IRAK1) and TNF receptor associated factor (TRAF)-6 (Saba, Sorensen et al. 2014). 
Similarly, miR-27a is associated with a plethora of pathophysiological processes in PE including 
angiogenesis (Urbich, Kaluza et al. 2012), inflammation (Xie, Cui et al. 2014), and obesity (Kang, Lu 
et al. 2013), (Bodnar, Ness et al. 2005), a risk factor directly related to PE.   However, SNP’s, a variation 
at a single position in a DNA sequence among individuals have been shown to affect miRNA target 
expression, possibly contributing to disease susceptibility (Clop, Marcq et al. 2006), (Yu, Li et al. 2007). 
A SNP variant of miR-27a and miR-146a, includes rs2910164 and rs895819 respectively, as reported 
in the dbSNP database Build 130 (NCBI 2009). 
 
The relationship between PE, co-morbid HIV infection and treatment with HAART remains unclear 
despite recent research (Frank, Buchmann et al. 2004), (Mattar, Amed et al. 2004), (Kalumba, Moodley 
et al. 2013), (Cassidy-Matthews 2015),  and  there is no consensus on the risk that HIV infected pregnant 
women have of developing PE compared with the general population. In South Africa, PE and HIV 
occur commonly and continue to remain leading causes of maternal mortality (Moodley, Pattinson et 
al. 2014), (Gebhardt, Fawcus et al. 2015). Moreover, reducing maternal mortality by 75% by 2015 is 
part of the millennium development goals of the World Health Organization (WHO) Nations  
(Osungbade and Ige 2011), which therefore consolidates the need to further investigate and improve on 















1.2. LITERATURE REVIEW 
1.2.1. Preeclampsia 
PE is defined as a blood pressure greater than or equal to 140 mmHg systolic or greater than or equal 
to 90 mmHg diastolic on 2 occasions at least 4 hours apart after 20 weeks of  gestation in a woman with 
previously normal blood pressure (Obstetricians and Gynecologists 2013). Globally, PE complicates 
approximately 2-10 % of pregnancies and is associated with 10-15% of direct maternal deaths overall 
(Duley 2009) . In South Africa, which is considered an upper middle income country, the prevalence of 
hypertensive disorders of pregnancy is approximately 18%  (Moodley and Kalane 2006). Although the 
etiology of PE remains unknown, many investigators now acknowledge that the diverse maternal 
symptoms of PE is related to a generalized dysfunction of the maternal endothelium (Sargent, 
Borzychowski et al. 2006) which appears to be part of an exaggerated systemic inflammatory response 
involving maternal leukocytes and pro-inflammatory cytokines (Raghupathy 2013). The sequence of 
events is proposed in 2 stages: a placental stage (stage 1) and a systemic stage (stage 2) as shown in 
Figure 1.1. 
                   
                    Figure 1.1:  Proposed stages of events in PE (Raghupathy, 2013)  
 
 
Severe maternal complications of PE include renal or hepatic failure, the “HELLP syndrome” 
(Haemolysis, Elevated Liver enzymes, Low Platelet count), eclampsia, stroke and death and perinatal 
complications include premature delivery, intra-uterine growth restriction (IUGR), neurological 
complications and foetal death (Lorquet, Pequeux et al. 2010). Despite extensive research, the treatment 
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of PE remains empiric and resolution is achieved after delivery of the placenta  (Lorquet, Pequeux et al. 
2010).  Current management strategies includes screening during antenatal visits, administration of anti- 
hypertensive therapeutic agents, assessment of organ damage, antenatal fetal surveillance, antenatal 
corticosteroids  and timeous delivery (NDoH2007). Currently, calcium supplementation, low-dose 
acetylsalicylic acid and magnesium sulphate are recommended for the prevention of PE and eclampsia 
respectively (WHO2011) . 
 
1.2.2. HIV and HAART  
 
 
                               Figure 1.2: Structure of the Human Immunodeficiency virus:   
                                                    (Source: science.howstuffworks.com) 
                                                
Globally, 35.3 million people were infected with HIV in 2012, and more than half of this infection 
occurred in women and girls of reproductive age. (Browne, Schrier et al. 2015),(UNAIDS 2010).  South 
Africa (SA)  has the biggest and most high profile HIV epidemic in the world, with an estimated 6.3 
million people living with HIV  and 200,000 deaths  from AIDS-related illnesses in 2013 (UNAIDS 
2014). During pregnancy , approximately 29% of antenatal clinic attendees test positive for HIV during 
screening in SA (NDoH2012). 
 
The transmission of the virus to the fetus can occur during pregnancy (intrauterine), labour and delivery 
(intrapartum), and after delivery (postpartum) mainly through breast feeding (De Cock, Fowler et al. 
2000). Maternal complications of HIV include spontaneous abortions, ectopic pregnancies, systemic 
infections such as respiratory and urinary tract infections and co-infection with tuberculosis (UNAIDS 
2012), (MacLeod and Rhode 1998). HIV has also been associated with obstetric haemorrhage, 
thrombocytopenia, anaemia and an increased risk of obstetric haemorrhage and complications 
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associated with caesarean section (MacLeod and Rhode 1998), (Adam 2015). Fetal complications 
include increased risk of stillbirth, infections, growth restriction and neonatal encephalopathy 
(Kennedy, Fawcus et al. 2012) (Pattinson, Hulsbergen et al. 2010). 
 
The treatment of HIV using antiretroviral therapy (ART) began with the first clinical trial of zidovudine 
in 1986 (Fischl, Richman et al. 1987). Almost a decade later, the concept of 3-drug therapy showed 
benefit with a 60% to 80% decline in rates of AIDS, death, and hospitalization and was incorporated 
into clinical practice (Palella Jr, Delaney et al. 1998). The role of the nonnucleoside reverse transcriptase 
inhibitor (NNRTI) efavirenz, "the third drug" in combination with 2 nucleoside RTIs (NRTIs) that 
constitute HAART was established in 1999 (Study 006) (Staszewski, Morales-Ramirez et al. 1999). 
Thereafter, a rapid evolution in drug related research has led to the usage of a variety of drugs which 
include  nucleoside/nucleotide reverse transcriptase inhibitors, such as emtricitabine, and tenofovir, 
nonnucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, protease inhibitors (PIs), 
such as ritonavir and  integrase inhibitors, such as raltegravir, among others.  
 
In South Africa, the use of HAART in pregnancy is guided by policy guidelines which include Fixed 
Dose combination (FDC). The FDC ART is one ARV pill which contains three drugs:  tenofovir (TDF), 
emtricitabine (FTC) and efavirenz (EFV) (Southern African 2013). Although serious side effects such 
as dyslipidaemia, hepatotoxicity and nephrotoxicity may occur with these drugs, the risk for adverse 
events for both the mother and the baby are low in the short term. (Browne, Schrier et al. 2015).  In 
pregnancy ART/HAART is used to reduce maternal viral replication and mother to child transmission 
of HIV (PMTCT) either by lowering plasma viral load in pregnant women or through post-exposure 
prophylaxis in their new-borns  (Autran, Carcelain et al. 1997), (Siegfried, van der Merwe et al. 2011). 
 
HAART, which usually comprises three drugs, has been advocated since 1996 and has successfully 
reduced the mother-to-child transmission rates to around 1-2% in some countries. (Siegfried, van der 
Merwe et al. 2011). However, it has been suggested that HAART could possibly influence the inhibitory 
effect of HIV on the development of  hypertensive disease in pregnancy and this risk may be enhanced 
by the  endothelial toxicity and vascular dysfunction associated with HAART (Browne, Schrier et al. 
2015), (Wang, Chai et al. 2007), (Kline and Sutliff 2008). There has not been a systematic review 
regarding the risk of developing hypertensive disorders in pregnancy among HAART recipients and 
data on the relationship between PE and HIV/HAART  is limited (Browne, Schrier et al. 2015). 
Challenges associated with HAART in the forthcoming years are likely to focus on more effective drugs 
with fewer side effects especially hepatotoxicity and to ensure provision of therapy to resource limited 








Cytokines are small secreted proteins and include lymphokines, monokines, chemokines and 
interleukins. They are produced predominantly by helper T cells (Th) and macrophages, and can act 
synergistically or antagonistically exerting an autocrine, paracrine or endocrine action (Zhang and An 
2007)  .  The classification of cytokines is shown in Table 1.1. 
Table 1.1 : Classification of cytokines .(Jun-Ming Zhang and Jianxiong , 2007)  
 
                         
 
Cytokines like interleukin (IL)-2, tumour necrosis factor (TNF)-α, and interferon (IFN)-γ are 
characteristic of T helper 1 (Th1)-type immunity and induce several cell-mediated cytotoxic and 
inflammatory reactions. T helper 2 (Th2)-type cells, on the other hand, secrete the Th2 cytokines IL-4, 
IL-5, IL-6, and IL-10 and are associated with humoral immunity (Romagnani 2000), (Mosmann and 
Sad 1996). A Th2-type immunity is associated with a normal pregnancy, whereas a strong Th1 reactivity 
is associated with proinflammatory cytokines such as IL-1, IL-2, IL-8, TNF-α, and IFN-γ and pregnancy 
related complications (Raghupathy 2013). 
 
In PE, proinflammatory cytokines are increased in the blood and blood leukocytes, and serum from 
women with PE have increased Th1/Th2 cytokine ratios and  increased levels of the cytokines IL-6 and 
TNF-α, (Szarka, Rigó et al. 2010). Levels of soluble TNF-α receptor, a more reliable marker for TNF 
activity, are also increased in PE as compared to normal pregnancies  (Kupferminc, Peaceman et al. 
1995). Additionally, a shift towards Th1-type immunity (expressed by the increased IL-2/IL-4 and IFN-
gamma/IL-4 ratios), and circulating levels of pro-inflammatory cytokines IL-6 and TNF-alpha, amongst 
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others, are elevated in PE compared with healthy pregnancy (Szarka, Rigó et al. 2010). Elevations in 
IL-8, IL-6, and IFN-γ have also been demonstrated in PE (Pinheiro, Martins-Filho et al. 2013). 
 
These findings suggest the overall pro-inflammatory systemic environment associated with PE. The 
relationship of inflammatory cytokines and endothelial dysfunction, a key feature in PE , is shown in 
Table 1.2. 
 
Table 1.2: Inflammatory cytokines and endothelial dysfunction (Raghupathy, 2013) 
 
                          
 
In HIV infection, the role of cytokines is complex as the rate of progression of the disease is variable 
and the pathophysiology is still not completely understood. However, elevated cytokine levels in HIV 
infection could have positive or negative effects on viral control or CD4+ T cell homeostasis (Keating, 
Golub et al. 2011). TNF-α and IL-2 have been shown to  enhance HIV replication in in vitro studies 
(Folks, Clouse et al. 1989), (Kinter, Poli et al. 1995) whilst in  contrast, IFN-α, IFN-γ  (Shirazi and Pitha 
1992),  appear to decrease HIV replication in tissue culture.  Earlier work has further demonstrated that 
chronic HIV infection, patients show elevations in serum or plasma TNF-α levels (Zangerle, Gallati et 
al. 1994).  
 
HAART has been shown to correct much of the inflammation induced by HIV at the level of CD4+ and 
CD8+ T cells (Almeida, Cordero et al. 2007), however whilst abnormalities in many serum markers 
improve  they do not necessarily resolve on HAART (French, King et al. 2009). Recent data from the 
SMART trial showed that elevated levels of C-reactive protein and IL-6 were associated with an 
increased risk of death in participants who received treatment (Kuller, Tracy et al. 2008). Changes in 
TNF-α and FGF-2 have been shown to be mitigated by HAART usage. Data from a population based 
study among women, showed HAART recipients to have fewer detectable differences in cytokines from 
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HIV uninfected persons when compared with untreated women, though TNF-α and FGF-2 were still 
different in the HAART compared to a negative  group (Keating, Golub et al. 2011). Moreover, cytokine 
levels associated with effective HAART usage are not identical to those in HIV seronegative women, 
highlighting the limitations of HAART to wholly correct the systemic inflammation associated with 




1.2.4. Epigenetics and miRNA’s 
 
           
Epigenetics refers to changes in gene expression that occur without alterations in DNA sequence  
(Roman, Dafashy et al. 2014). These modifications can occur through various mechanisms, but most 
significantly, by post-transcriptional gene regulation (Roman, Dafashy et al. 2014). Epigenetic 
modifications, especially during pregnancy complications, are significant as they can lead to an altered 
placental phenotype (Chan, Fish et al. 2004). 
 
Epigenetic factors within the placenta have been implicated in the pathogenesis of PE (Nelissen, van 
Montfoort et al. 2011).  Both conventional and microarray approaches have identified a substantial 
number of differentially expressed (DE) genes in the transcriptome of human placentas from PE 
compared with normotensive healthy term deliveries (Sitras, Paulssen et al. 2009), (Mouillet, Chu et al. 
2011), suggesting differential gene expression may be associated with the pathogenesis of PE. 
 
 
HIV was among the first pathogens implicated in the induction of an epigenetic change in host cells. 
For example, terminating the transcription of IFN-γ may result in blocking the host immune response 
(Ay, Banati et al. 2013).  Epigenetic mechanisms are also implicated in mechanisms of drug resistance 
in HIV infected cells. Mutant viral genomes cause alterations of the viral enzymes reverse transcriptase, 
protease and integrase resulting in the development of clinical resistance to antiretroviral drugs  (Shafer, 
Rhee et al. 2007). 
 
 
MicroRNAs have been linked with pregnancy complications in epigenetic studies (Choudhury and 
Friedman 2012). MiRNAs are endogenous, highly conserved, small noncoding RNAs (≈22 nucleotides) 
that regulate the expression of target mRNAs (Bartel 2004). They play an important role in mediating 
placental epigenetic changes, acting as silencers of post-transcriptional gene expression by base pairing 
with, rather than degrading, mRNA. By targeting mRNA, they are able to upregulate or downregulate 





The biogenesis of miRNA’s involves two main pathways – a canonical and an alternate pathway.  The  
canonical pathway, driven by RNase III enzymes generates the majority of animal miRNAs  (Ghildiyal 
and Zamore 2009). The biogenesis starts with RNA polymerase II-dependent transcription of a miRNA 
gene locus, generating a long primary transcript known as pri-miRNA that can fold into a hairpin 
structure (van Kouwenhove, Kedde et al. 2011). Cleavage occurs near the base of each pri-miRNA 
hairpin by the microprocessor complex that contains a RNase III enzyme called Drosha and its cofactor 
DGCR8 (DiGeorge syndrome critical gene 8) (Han, Lee et al. 2006). DGCR8 is a double-stranded RNA 
(dsRNA) binding protein that recognizes the proximal ∼10 bp of stem of the pri-miRNA hairpin, 
positioning the catalytic sites of the RNase III enzyme Drosha (Han, Lee et al. 2006). 
 
 
The alternative pathway for miRNA biogenesis are utilised by mitrons, a subset of miRNAs (Ruby, Jan 
et al. 2007) located within short introns, and once splicing is complete, a debranching enzyme generates 
the pre-miRNA-like hairpin structure. (Baley and Li 2012). These pre-miRNAs are recognised by a 
complex of exportin-5 (Exp5) and RAN-GTP (van Kouwenhove, Kedde et al. 2011) and then exported 
to the cytoplasm by Exp5, where they are cleaved into mature 20-25 nucleotide miRNA duplexes by 
another RNAse III endonuclease, DICER, and its double stranded RNA binding cofactor the RNA-
binding protein: trans- activation response (TAR) RNA binding protein (TRBP) (Winter, Jung et al. 
2009), (Bronze-da-Rocha 2014). 
 
 
The passenger strand is typically degraded, while the guide strand is incorporated into RNA- induced 
silencing complex (RISC) and then mediates mRNA degradation or translational inhibition (D'Anzeo, 
Faloppi et al. 2014). The Canonical and Major Alternative miRNA Biogenesis pathways involved in 











Figure 1.3: Canonical and Major Alternative miRNA Biogenesis Pathways in Animals. (Yang et al., 
2011) 
 
The regulation of placental development by miRNAs has been shown through the control of trophoblast 
cell proliferation, migration, invasion, apoptosis, and angiogenesis (Fu, Brkić et al. 2013). MiRNA’s 
have diverse effects on PE pathogenesis and could be a potential causal factor in the pathophysiology 
of PE. The evidence from a systematic review on the role of miRNA’s in PE revealed that miRNAs 
interfere with angiogenesis during early pregnancy by dysregulating angiogenic factors (sFlt-1, sEng , 
VEGF and PlGF) and their receptors (Harapan and Yeni 2015). Dysregulation of these angiogenetic 
factors also induce hypertension during the clinical stage of PE. Additionally, miRNAs also induce 
hypertension by inducing the production of AT1-AA and targeting several vasodilators such as 
prostacyclin, 17β-estradiol, H2S and NO (Harapan and Yeni 2015) . 
 
 
MiRNAs also play an important role in modulating HIV-1 infection, which has evolved several 
mechanisms to promote its continued existence. Triboulet et al., demonstrated the role played by 
cellular miRNAs during HIV-1 infection: (1) by knocking down Drosha and Dicer, (miRNA processing 
proteins), (2) binding to and co- localizing with proteins of the RISC complex (Ago2) and (3) negatively 
regulating HIV-1 gene expression by preventing viral mRNA association with polysomes (Triboulet, 
Mari et al. 2007). Overall, HIV-1-mediated modulation of cellular miRNAs, although not directly 
essential for basic replication stages, could play a role in pathogenesis and disease progression 
(Swaminathan, Navas-Martín et al. 2014). The association of HIV on proteins involved in miRNA 
biogenesis pathway is shown in Figure 1.4. 
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MiR-27a is a member of the intergenic 23a ~ 27a ~24-2 cluster and is involved in cell cycle control, 
proliferation and differentiation of various cell types (Zhu 2013). It is ~ 22 nucleotides long and forms 
one strand of the RNA duplex (Ma and Chen 2012). It has been implicated in many metabolic and 
angiogenic processes as well as in oncogenesis. It promotes angiogenesis by targeting the angiogenesis 
inhibitor SEMA6A, which controls repulsion of neighbouring endothelial cells (Urbich, Kaluza et al. 
2012). In the process of adipogenesis, it plays an anti-adipogenic role by targeting prohibitin and 
impairing mitochondrial function (Kang, Lu et al. 2013). MiR-27a also targets peroxisome proliferator 
–activated receptor gamma (PPAR-ɣ) to prevent the terminal differentiation of adipocytes and 
negatively regulates lipoprotein lipase in adipocytes  (Bouvy-Liivrand, Heinäniemi et al. 2014), thus 
playing a role in lipid homeostasis.   In inflammation, its role is demonstrated by enhanced expression 
of pro-inflammatory cytokines, such as IL10 when upregulated in Tlr2- or Tlr4-activated macrophages 
(Xie, Cui et al. 2014).  In cardiovascular disease, it is associated with angiogenesis and endothelial 




                                      
            Figure 1.5: Importance of hsa-miR-27a in oncogenesis, proliferation and differentiation 
                                       (Source: molecular-cancer.biomedcentral.com)    
   
The oncogenic role of miR-27a has been demonstrated in renal cell carcinoma (Gottardo, Liu et al. 
2007), in cervical cancer  (Wang, Tang et al. 2008), gastric adenocarcinoma  (Liu, Tang et al. 2009) and 
in breast cancer (Guttilla and White 2009). In addition to the regulatory role of miR-27a in diverse 
processes, miR-27a is also influenced by viral infections. It has been observed that both host and virus 
contain mechanisms to regulate miRNA expression and/or activity (Buck, Perot et al. 2010). 
Polymorphisms of miR-27a have been associated with breast cancer risk and gastric mucosal atrophy 
(Yang, Schlehe et al. 2010), (Arisawa, Tahara et al. 2007).  
 
Interestingly, a recent study showed that PPAR-ɣ also inhibits NF-kB, which promotes pro-
inflammatory cytokine production in the lungs of septic mice (Wang, Ruan et al. 2014). A knock down 
of miR-27a down regulated pro-inflammatory cytokines IL-6 and TNF-α and pulmonary inflammation, 
indicating decreased inhibition of PPAR-ɣ (Wang, Ruan et al. 2014), and may represent the interactive 
relationship between miR-27a and miR-146a.  
 
MiR-146a ( miR-146a ; has – miR – 146 a - 5p ; 5′- U G A G A A C U G A A U U C C A U G G G U 
U - 3′; 59 % A + U; NR_029701 ; http:// atlasgeneticsoncology.org/Genes/ GC_MIR146B.html), is 
encoded from a single locus at chromosome 5q33.3 in humans and is a rapidly induced, pro-
inflammatory miRNA with a relatively short half-life of about 1.5–2 h in humans (Alexandrov, Dua et 
al. 2014) . MiR-146a has been found to be inducible upon stimulation with lipopolysaccharide (LPS) 
in a NF- kB dependent manner, and to target the TRAF 6) and IL-1 receptor associated kinase 1 (IRAK-
1) gene. (Taganov, Boldin et al. 2006). A diagrammatic representation of this pathway is shown in 
Figure 1.6.  MiR-146a may play important roles in many pathophysiological and physiological 
processes such as the innate immune and inflammatory response, virus infection and human diseases 
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such as autoimmune disease and cancer. (Li, Chen et al. 2010). Manipulation of miR-146a expression 
may also represent potential new therapy for several human diseases and serve as a biomarker for 
disease diagnosis, prevention and treatment (Li, Chen et al. 2010). 
 
 
             
 





SNPs form the majority of genetic variations in the human population and are at the forefront of current  
human genomic, epidemiological and pharmacogenomic studies focusing on the identification of 
genetic variations responsible for common and complex diseases (Lee and Shatkay 2008). A SNP is a 
DNA sequence variation occurring when a single nucleotide adenine (A), thymine (T), cytosine (C), or 
guanine (G) in the genome (or other shared sequence) differs between members of a species or paired 
chromosomes in an individual (ISOGG 2015).  
SNP’s may not cause a  particular disorder, however maybe associated with certain diseases and may 
be associated with an individual's genetic predisposition to develop a disease (Sachidanandam, 
Weissman et al. 2001). SNPs, located either in the pre-miRNAs or within miRNA-binding sites, have 
been shown to affect miRNA target expression, thereby possibly contributing to disease susceptibility 
(Clop, Marcq et al. 2006), (Yu, Li et al. 2007).  A common T/C miR-27a SNP (rs 895819), occurs in 
the terminal loop, of the pre-miRNA  (Shi, Li et al. 2012) and a common G/C SNP (rs 2910164), located 
within the seed sequence of miR-146a (Jazdzewski, Liyanarachchi et al. 2009), may alter the expression 
of miR-27a and miR-146a respectively.  However, whether genetic variants confer differences in the 
14 
 
expression of the miRNA’s in PE, HIV or their associated features is unclear. Reliable identification of 
disease-causing SNPs is expected to lead to early diagnosis, personalized treatment and targeted drug 
therapy in the future (Lee and Shatkay 2008).  















































1.3.   RESEARCH QUESTIONS: HYPOTHESIS, AIMS AND OBJECTIVES  
 
Preeclampsia (PE) and HIV/AIDS contribute significantly to adverse maternal and perinatal outcomes 
globally. The relationship between PE and HIV /HAART remains controversial and despite extensive 
research, the pathophysiology of both conditions is not fully understood. This study therefore 
investigated the clinical and biochemical effects associated with HAART as well as immunological and 




(1) HAART is associated with a potential restoration of the immune system during pregnancy  and 
affects the clinical  and biochemical features  associated with  co-morbid PE 
(2) HAART impacts on the pro-inflammatory environment in HIV infected women with PE 
through alterations in pro-inflammatory cytokines.  
(3) Gene polymorphisms contribute to PE susceptibility and/or some of the associated risk features 
and is differentially regulated in the presence of HIV infection and HAART. 
 
1.3.2. Aims: 
To test this hypothesis, four areas were investigated in this study, aimed at further analysing the 
relationship between PE and HIV/HAART,  viz.,    (1) clinical parameters, (2) biochemical/laboratory 
indices, (3) immunological factors (pro-inflammatory cytokines) and (4) epigenetic factors (microRNA 
SNPs: miR-27a and miR-146a), in 4 groups of Black South African women, considered to be high risk 
for these conditions, viz., : (1) normotensive HIV negative , (2) normotensive HIV positive , (3) PE HIV 
negative  and (4) PE HIV positive . 
1.3.3. Objectives: 
The specific objectives of the study were to: 
(1) To determine the association of HIV and HAART with clinical and routinely used biochemical 
/laboratory indices, and to assess complications in women with co-morbid PE. 
(2) To determine the effects of HAART on pro-inflammatory cytokines IL-2, TNF-α , IFN-ɣ and 
IL-6 in women with PE  
(3) To determine the role of 2 single nucleotide polymorphisms (SNP) miR-27a (rs895819 T>C), 
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Title: The association of HIV and HAART with clinical and biochemical indices in    
          African women with preeclampsia 
            
Objective: To determine whether clinical and biochemical features associated with preeclampsia are 
significantly altered in the presence of HIV and HAART.  
 
Methods: A prospective observational cohort study was conducted between July 2013 and September 
2014 at Prince Mshiyeni Memorial Hospital in Durban, South Africa. One hundred and ninety three 
women (45 HIV infected preeclamptic women on HAART and 53 uninfected preeclamptic women and, 
45 normotensive HIV infected women on HAART and 50 normotensive uninfected women) were 
enrolled and followed until delivery. Specific demographic data, clinical features, laboratory indices, 
and complications were analysed. 
  
Results:  There were no significant differences in the clinical features and laboratory indices between 
the groups, except for gamma glutamyl transferase which was significantly elevated in the preeclamptic 
HIV/HAART group (p=0.001). Perinatal and maternal complications were similar and there were no 
maternal deaths.  
 
Conclusion: The clinical features, laboratory indices, and complications among HIV infected 
preeclamptic women on HAART is similar to uninfected preeclamptic women. Current guidelines 
remain appropriate, however serial hepatic function tests are necessary. The prevention of obesity is 
also necessary to reduce long term cardiovascular complications associated with these conditions.  
 
 










Preeclampsia is a multi-organ disorder of pregnancy associated with significant maternal and neonatal 
morbidity and mortality [1]. It complicates 2-10% of pregnancies, and is associated with 10-15% of 
direct maternal deaths overall [2]. Maternal manifestations of preeclampsia include multisystem 
involvement whilst adverse perinatal outcomes include small for gestational age (SGA), fetal growth 
impairment (FGI) and stillbirths. 
 
AIDS-related illness is the leading cause of death and disease among women of reproductive age in 
low and middle income countries, particularly in Africa [3]. 
It is estimated that approximately 5 % of pregnancy related deaths worldwide, and 25% in Sub –
Saharan Africa are attributable to HIV [4]. Although the use of anti-retroviral (ARV) therapy has 
significantly reduced the rate of mother to child transmission of HIV, it is also associated with 
perinatal complications [5]. 
 
In South Africa, a middle income country, preeclampsia (and other hypertensive disorders of 
pregnancy(HDP) , and   HIV/AIDS,  are implicated by the National Confidential Enquiries Committee 
on Maternal Deaths in South Africa(NCCEMD)  as leading causes of maternal deaths. (Saving Mothers 
Reports, 2008 -2010 and 2011-2013) [6]. 
 
The relationship between HIV infection and preeclampsia remains unclear despite recent research. 
While some studies have found that preeclampsia is less common in HIV infected women, others have 
shown that HIV infected women develop a higher rate of preeclampsia [7, 8]. Currently, there is no 
consensus on whether pregnant women who are HIV infected are at lower, equal or higher risk of 
developing preeclampsia than the general population, and the treatment of these conditions still remains 
largely empirical. Furthermore, there is a lack of data on the clinical and biochemical alterations that 
may occur when preeclampsia and HIV infection co- exist.   
 
We hypothesized that the clinical features , blood pressure measurements , biochemical indices and 
outcomes in HIV infected preeclamptic women on HAART is similar to uninfected preeclamptic 
women , and may be associated  with  HAART induced immune reconstitution. To elucidate the former, 
we analysed these parameters in a cohort of patients with preeclampsia and HIV, at a large regional 
hospital over a 14 month period.  
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Materials and Methods: 
 
Study design: 
The study is a prospective observational cohort study conducted between July 2013 and September 
2014 at the Maternity Unit of Prince Mshiyeni Memorial Hospital. The hospital is  a large regional 
hospital in southern Durban, KwaZulu-Natal that serves a semi –urban population of approximately 2 
million people, where approximately 12 000 deliveries are conducted annually. The inclusion criteria 
included preeclamptic and normotensive women with and without HIV infection. Women with 
gestational hypertension, renal disease, diabetes mellitus, chronic hypertension and collagen vascular 
disease were excluded. Overall, one hundred and ninety three (193) women were recruited by 
convenience sampling on admission and followed until after delivery. Specific demographic, clinical 
and laboratory data were recorded and analysed in 4 groups i.e. HIV uninfected normotensive, HIV 
infected normotensive, HIV uninfected preeclamptic, HIV infected preeclamptic groups. 
  
Study setting: 
The majority of women who deliver at the unit are African women of Zulu ethnicity. The antenatal HIV 
seroprevalence rate in the area is approximately 37 % [9]. The incidence of hypertensive disease (HDP) 
in the region is approximately 12-18 % [10] .Following institutional and University (UKZN) ethical 
approval, written informed consent was obtained from all patients. The management of patients at the 
study site included a full clinical assessment, relevant investigations, antihypertensive medications, 
monitoring and timeous delivery, as described in the Maternity Guidelines of South Africa [11].  
 
Patient selection: 
All patients enrolled in the study were referred from local clinics within the catchment area prior to 
booking at the hospital, or booked directly at the institution’s Maternity Unit, where they were recruited 
and followed up until the early postpartum period. To maintain ethnographic and anthropometric 
consistency, all patients chosen were of Black African origin, resident in the same geographical location 
and of Zulu ethnicity. Patients selected in the study were non-smokers, did not consume alcohol or 
recreational drugs, and all HIV infected patients were on daily  fixed dose combination (tenofovir 
300mg, emtricitabine 200mg , efavirenz 600mg ) of HAART (highly active antiretroviral therapy ), in 
terms of the National  guidelines [12]. Calcium supplementation was administered routinely to all 





Preeclampsia was defined as a blood pressure greater than or equal to 140mmHg systolic or greater than 
or equal to 90 mmHg diastolic on 2 occasions at least  4 hours apart after 20 weeks of gestation in a 
woman with previously normal blood pressure [13]. All patients had proteinuria >= +1 on urine dipstick 
testing. Data on all patients was obtained from the institution’s maternity case records and laboratory 
data from the National Health Laboratory Services computerised database at the institution. HIV was 
diagnosed on a rapid test kit, and blood pressure recordings (highest BP) were taken at initial booking, 
and during the antenatal, intrapartum and postpartum periods. Weight was categorised as: normal 
weight (BMI: 18-<25), overweight (BMI: 25-<30) and obese (BMI: 30+). Early onset preeclampsia was 
defined as preeclampsia occurring before 34 weeks of gestation.  Severe preeclampsia was diagnosed 
when any of the following was present: systolic BP ≥ 160 mmHg, diastolic BP ≥110 mmHg, impaired 
renal /liver function, thrombocytopenia, pulmonary oedema, cerebral /visual disturbances and persistent 
right upper quadrant/epigastric pain unresponsive to treatment, and fetal criteria including fetal growth 
impairment , oligohydramnios and fetal death [13]. 
 
Statistical analysis:  
Statistical analysis was done using SPSS® version 22. The descriptive statistics are tabulated. 
Comparisons of mean across groups were done using the Kruskal– Wallis test, a non-parametric test 
for variables that were found not to be normally distributed. The student t test was used to compare 
difference in means between two groups mainly PE HIV negative and PE HIV positive. In all the tests, 
we used 𝛼 = 0.05 as the level of significance. The decision to reject the null hypothesis is based on the 




Figure 2.1. shows the distribution of patients with preeclampsia and HIV infection. Ninety eight 
women (45 HIV infected preeclamptic women on HAART i.e.46%, and 53 uninfected preeclamptic 
women i.e.54%) were recruited into the study and followed until delivery and discharge from the 
institution. A control group of 95 women (50 normotensive uninfected i.e. 53% and 45 normotensive 

















   
 
Figure 2.1: Flow diagram of the study population 
 
 
The characteristics of the patients that were analysed in the study is shown in Table 2.1.  The mean age 
of the women was 26.5 years and HIV infected women with pre-eclampsia were significantly older than 
uninfected women with preeclampsia. Most women i.e.197 (93%), booked at a local clinic at an average 
of 22 weeks of gestation and had 4 antenatal clinic visits. Overall, women in all groups were overweight 
/obese (BMI =31).The mean CD4 cell count between normotensive and pre-eclamptic HIV infected 
women was not significantly different.  
 
The clinical and biochemical data of women with preeclampsia are shown in Table 2.2 and Table 2.3 
respectively. The prevalence of early onset preeclampsia (EOPE) and severe preeclampsia was 32(33%) 











Total patients (n=193; 100%) 
Preeclamptic (n=98; 50.7%) 
 
 
Normotensive (n=95; 49.2%) 
 
HIV -  
(n=50; 52.6%) 




HIV infected  
(n= 45; 47.3 %)  
 
HIV infected 




Table 2.1. Clinical Characteristics of participants  
 
Variable  PE HIV  
uninfected 
(Grp 1) 








  uninfected 
    ( Grp 3) 




    (Grp 4) 
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 Total 









Age (n, %)  















28 ± 6.4 
17-46 
192(99) 0.002 0.003 
Parity  
(n, %  )  












  1 (25.0) 
 
 
 17(25.8)   
 31(25.2) 









  66 (34) 
 123(64) 
      4 (2) 
0.006 
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    9(17) 
  32(60) 



























  70(37) 
  79(42) 








Abbreviations: GA = gestational age, BMI = Body Mass Index, MOD= mode of delivery, ELCS= 
elective caesarean section, EMCS= emergency caesarean section, VD= vaginal delivery, SD=standard 




In most cases, blood pressure was controlled using a single therapeutic agent (usually methyl dopa), 
with no significant difference the number of antihypertensive drugs used to control blood pressure 
between HIV infected and uninfected groups (Table 2.2) . There was no significant difference in the 




The analysis of the biochemical indices investigated showed no significant differences apart from 
gamma glutamyl transferase (GGT), which was significantly raised among HIV infected preeclamptic 
women. CD4 counts were analysed in the HIV infected preeclampsia and normotensive women, as CD4 
testing is not routinely performed in HIV uninfected women in the study setting. Table 2.4 shows the 
perinatal and maternal outcomes among the women with preeclampsia. The mean birth weight overall, 
including normotensive women was 2.82 kg, and more female babies were born compared with males 


























Table 2.2: Clinical characteristics of women with preeclampsia 
 








P value   
EOPE (n, %) 
 
14(26) 18(40) 32(33) 
 
0.153 





















  7 (7) 






   8 (8) 























BK SYS (mmHg) (n, %) 




 126± 22.4 
  91-198 
 45(100) 
134± 18.4 
  94-194 
 
98(100) 0.070 































































PP DIA (mmHg) (n, %) 









Abbreviations: n=total number, EOPE=early onset pre-eclampsia, PE=preeclampsia 
AHT=antihypertensive drugs, BK= booking, SYS=systolic. DIA=diastolic,  







Table 2.3: Laboratory Data: 
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p value  Total 
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ALT (U/l) (n, %)) 

















AST (U/l) (n, %) 





























Abbreviations: WCC= white cell count, Hb=haemoglobin, Cr=creatinine, ALT=alanine 
transaminase, AST=aspartate transaminase, GGT=gamma glutamyl transferase .LDH= lactate 
dehydrogenase, UA=uric acid, * = significant difference  
 
 
Babies born to pre-eclamptic women were smaller compared with normotensive women (2.49 kg vs 
3.14 kg), but similar between HIV infected and uninfected women with pre-eclampsia (2.4kg vs 
2.5kg). Other outcomes were similar between these 2 groups. There were no maternal deaths during 











     HIV  
   infected  




Perinatal: (n, %) 
Preterm delivery                                                       
        IUGR                                                                       
        Macerated stillbirths                                                     
        Fresh stillbirths                                                             
        Early neonatal death                                                    
        Intrauterine death                                                              
        IUGR                                                                      
        Apgars (mean) (1 min)                                                         
                                 (5 min)                                                       
        Birth weight (kg) (mean)                                                    
        Ventilation (ICU)                                                                 
        Birth defects (any)                                                                      
 
 
12 (27)  
  7 (16) 
  1 (2) 
  1 (2) 
  1 (2) 
  2 (4) 
  6 (13) 
  7 (16) 
  8 (18)  
  2.4   
  0 (0) 







0 (0)  







Termination *                          
         Abruptio placentae                  
         HELLP **                               
         Eclampsia                                         
         Maternal deaths                       
 
 
1(2)     
2(4) 
1(2)      
0(0)    








delivery before 28 weeks for maternal reasons 
      ** (haemolysis, elevated liver enzymes, low platelets)   






Our data reveal that the clinical parameters, laboratory indices and complications associated with 
preeclampsia are not significantly altered in the presence of HIV infection and treatment with HAART. 
However, significant increases were found in gamma glutamyl transferase (p=0.001) among 
preeclamptic women on HAART. This may suggest a compounding effect on the liver, which is a target 
organ for preeclampsia and the side effects of HAART. 
The literature on HIV infection, antiretroviral regimens and preeclampsia is controversial. Data on the 
impact of HIV on preeclampsia is inconsistent and currently there is no consensus on the risk that HIV 
infected women have of developing preeclampsia. In  South Africa , Frank et al,[8] showed no reduction 
in the risk of developing preeclampsia /eclampsia among untreated HIV infected women compared with 
HIV negative women ( 5.7% vs 5.2% ;p=0.61.). In contrast, Kalumba et al, [7] found that the rates of 
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preeclampsia are lower in HIV infected women. Internationally, a Spanish group reported a 
significantly higher risk for preeclampsia with HIV [14]. 
In view of the heterogeneity associated with the existing studies, we took a different approach to the 
investigation of HIV infection and preeclampsia by evaluating the biochemical indices and clinical 
parameters used frequently in the management HIV infected preeclamptic women on HAART 
compared with uninfected preeclamptic women. We further evaluated the maternal and fetal 
complications in these groups, with the aim of making recommendations for clinical management based 
on differences that may exist. To our knowledge, this is the first study to evaluate demographic, clinical 
and laboratory comparisons collectively in these conditions.    
Preeclampsia has been associated with oxidative stress and cellular sources such as CD4+ T cells have 
been implicated [15]. CD4+ cells are generally decreased in preeclamptic women when compared to 
normal pregnancy [16]. In our comparison of CD4+ cells in  HIV infected preeclamptic women with 
HIV infected controls, we did not find  a significant difference (436 vs 432; p=0.40). Our findings differ 
from Kalumba et al, who showed significant increases in CD4 + among HIV positive women with 
preeclampsia (304 vs 208, p=0.008) [7]. In contrast to Kalumba et al. who suggest that the immunity 
was less affected in those who developed preeclampsia, our findings do not show an effect on immunity 
in those who developed preeclampsia. We also found a non-significant decreases in leucocyte counts 
in the HIV infected group.  Leucocytes are however, also influenced by other factors e.g. disease 
progression, infections and drug treatment, which were not evaluated independently.    
 
The utilisation of platelet counts, as well as renal and hepatic function tests remain major determinants 
in the clinical management and timing of delivery in patients with preeclampsia and associated 
complications like HELLP syndrome (haemolysis, elevated liver enzymes, and low platelets).  Lower 
platelet counts were found in the HIV infected pre-eclamptic cohort and may represent a compounding 
effect, as both conditions are associated with reduced counts independently [17,18]. Laboratory tests of 
renal function (i.e. urea, creatinine, uric acid) were not significantly altered. Among the laboratory 
analytes of hepatic function evaluated, we found non-significant increases in LDH (630 vs 1052; 
p=0.39), but a significant increase in gamma glutamyl transferase (GGT) (26.9 vs17.1p=0.001). Our 
findings are consistent with other studies that show elevated levels of LDH and GGT in preeclampsia, 
and with antiretroviral therapy [19-21]. We did not find a significant difference in the haemoglobin 
levels between the groups (10.8 vs 10.9, p=0.56). The association of anaemia in pregnancy with lower 
CD4 counts in HIV infected women on antiretroviral therapy has been shown in a recent study [22]. 
We did not find a significant association of HIV with either early or severe preeclampsia, however 
further studies which evaluate the onset of infection, timing of HAART, and stage of disease 
progression are required in future long term studies to provide more specific data. HIV infection did 
not significantly affect the highest blood pressure levels at booking or in any of the antenatal, 
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intrapartum or postpartum periods of confinement. The use of additional antihypertensive drugs to 
control blood pressure was also not required in these patients (Table 2)  Intrapartum blood pressure 
values, however, are limited by confounding variables such as pain, the stage of labour and analgesia 
used  during labour , and did not apply to patients undergoing elective surgery. 
Of concern, is the higher though non-significant BMI values (39.4 and 30.1) in both HIV infected 
groups (Table 1). Preeclamptic women with HIV had the highest BMI (39.4) compared with other 
groups. These findings may be associated with dietary habits, lack of exercise, genetic factors and diet 
related counselling offered during anti -retroviral treatment. Our findings are consistent with Wand et 
al, who recently showed a high prevalence of obesity among HIV infected women in our province [23]. 
Older age and lack of education were also found to be significant predictors of obesity [23].  
 
Data on the association of antiretroviral therapy and preeclampsia are also inconsistent [24].   The use 
of HAART has also been associated with increased morbidity and adverse outcomes in earlier studies 
[13]. We did not find a significant association of HIV with maternal and perinatal outcomes in the 
cohort we analysed. (Table 4) Marginal differences were observed with slightly more preterm deliveries 
in the positive group, presumably due to higher rates of underlying infection, but fewer cases of growth 
impairment. Our findings are consistent with other studies that did not confirm adverse associations 
[25], however, our study was limited by a small sample size and larger, longer term studies are required 
to provide more accurate data. Further limitations in our study were the absence of an untreated HIV 
infected group, the inclusion of which would be unethical under the existing National Guidelines [12]. 
Further larger studies that evaluate the immune status of infection preconceptually, and track changes 
throughout pregnancy in relation to the development of preeclampsia and its sequelae will provide 
significant information on the relationship between these conditions. 
 
Conclusion: 
HIV infection treated with HAART is not associated with significant differences in the biochemical 
indices, clinical features or maternal and fetal outcomes in women with preeclampsia. The restoration 
of the immune system associated with the use of HAART, may facilitate the immunological responses 
in preeclampsia similar to that occurring in HIV uninfected women, and may explain the similarities in 
the clinical and laboratory manifestations in these patients. Current clinical guidelines on the 
management of HIV infected preeclamptic women appear to remain appropriate, however frequent 
evaluation of hepatic function in these women will enable early detection of hepatic toxicity. Strategies 
for the prevention of obesity, which may complicate long term cardiovascular and metabolic effects 
associated with preeclampsia, are necessary. Further research on immune restoration associated with 
HAART in pregnancy, will improve our understanding of these conditions, which still remain a 
significant health care challenge.   
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Synopsis: HIV and HAART are associated with significant decreases in pro-inflammatory cytokines 












Preeclampsia and HIV/AIDS are inflammatory conditions that contribute significantly to adverse 
maternal and fetal outcomes.  The immune reconstitution effects of HAART on inflammatory mediators 
has not been adequately studied in pregnancy and may impact on the inflammatory cytokine network 
in women with co-morbid preeclampsia.   
Aim: 
To evaluate the changes in pro-inflammatory cytokines IL-2, TNF-α, IFN-ɣ and IL-6 in HIV infected 
preeclamptic women on HAART.  
Methods: 
 A prospective experimental study was conducted at Prince Mshiyeni Memorial Hospital between July 
2013 to September 2014 .One hundred and ninety three pregnant women were recruited into 4 groups : 
uninfected normotensive (50;26% ),infected normotensive(45;23%),uninfected preeclamptic (53;28%) 
and infected preeclamptic women (45;23%).  Serum levels of cytokines TNF-α, IFN- γ, IL2 and IL6 
were determined, using commercially available kits and Cytometric Bead Array (CBA). Comparative 
data was recorded and analysed descriptively.    
Results:  
In the control group i.e. normotensive groups, significantly lower values were found in IL-2 (p=0.010), 
TNF-α (p=0.045), and IL-6 (p=0.005), and a non-significant decrease was observed in IFN-ɣ (p=0.345) 
in HIV infected women on HAART compared to uninfected controls. In the experimental group i.e. 
preeclamptic women, significantly reduced levels were observed in IL-2 and TNF-α (p=0.000; p=0.000) 
and non-significant decreases were observed in IFN-ɣ and IL-6 (p=0.023; p=0.086) in HIV infected 
women on HAART compared with uninfected preeclamptic women.  Non- significant differences were 
observed between uninfected preeclamptic and normotensive women.  
Conclusion:  
In uncomplicated/normotensive pregnancies, HAART is associated with significant decreases in IL-2, 
TNF-α and IL-6, and in preeclamptic women, it is associated with significant decreases in IL-2 and 
TNF-α. These findings suggest that HIV/HAART impacts on pro-inflammatory cytokines in women 
with co-morbid preeclampsia and provides a platform for further research on immune reconstitution 
effects of HAART during pregnancy, and the development of potential immune modulation therapies 
for the management of preeclampsia.  




Preeclampsia(PE), a multi-organ hypertensive disorder of pregnancy and HIV/AIDS (human 
immunodeficiency virus/acquired immunodeficiency syndrome) are associated with significant 
maternal and perinatal morbidity and mortality, especially in poor resourced countries(WHO 2009, 
Backes, Markham et al. 2011, Moodley 2014). The treatment of preeclampsia (PE) still remains 
empiric, and resolution is achieved by delivery (Nääv, Erlandsson et al. 2015). Highly active 
antiretroviral therapy (HAART) has been shown to successfully reduce plasma HIV-1 viral load and 
vertical transmission rates in pregnancy (Autran, Carcelain et al. 1997, Volmink, Siegfried et al. 2007), 
and is now integrated with the management of HIV infection in pregnancy (NDH 2013).   
However, there is no consensus on the relationship between these conditions as data on the impact of 
HIV on the rate of PE are conflicting (Kalumba, Moodley et al. 2013). HAART may influence the 
postulated inhibitory effect of HIV on the development of hypertensive disorders during pregnancy 
(Browne, Schrier et al. 2015). Although the underlying immunological changes in PE and HIV is not 
completely understood, it is generally accepted that both conditions are associated with inflammation 
(Deeks 2011, Catarino, Santos-Silva et al. 2012). Inflammation is mediated by a variety of soluble 
factors, including a group of secreted polypeptides known as cytokines (Shaikh, Sharma et al. 2011). 
Cytokines  can be classified as pro and anti –inflammatory and are considered as important initiators 
and mediators of inflammation and endothelial dysfunction (Raghupathy 2013). Cytokines such as 
interferon gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α), are characteristic of T helper 1 
(Th1) type immunity and mediate several cell mediated cytotoxic and inflammatory reactions 
(Mosmann and Sad 1996, Romagnani 2000). Interleukin (IL)-2  plays a critical role in regulating 
cellular and humoral chronic inflammatory responses; whilst IL-6, which also has anti-inflammatory 
properties, is also observed in many chronic inflammatory and autoimmune disorders and serves as a 
marker for the systemic activation of pro-inflammatory cytokines (Hirano and Kishimoto 1989, Shaikh, 
Sharma et al. 2011). 
Preeclampsia is associated with a generalized systemic inflammatory response and subsequent release 
of pro-inflammatory cytokines that may trigger the maternal disease (Sargent, Borzychowski et al. 
2006). Increases in the IL-2/IL-4 and IFN-γ /IL-4 ratios, as well as elevated circulating levels of IL-6 
and TNF-α, has been reported suggesting a pro-inflammatory systemic environment when compared to 
normal pregnancy (Martínez-Varea, Pellicer et al. 2014). 
In the progression of HIV infection, a Th1 (pro-inflammatory) to Th2 (eosinophilic/anti-inflammatory) 
cytokine shift has been observed, which appears to be counteracted with the usage of HAART (Fiore, 
Newell et al. 2006). Data on the immune reconstitution effects of HAART on pro-inflammatory 
cytokines in HIV infected women with PE is lacking. To further understand the effects of HAART on 
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the inflammatory cytokine network in HIV infected pre-eclamptic women, we investigated IL-2, TNF-
α, IFN-γ and IL-6 in women during the third trimester of pregnancy.  
 
Materials and methods: 
 
Study population and sample collection 
Institutional ethical and hospital regulatory permission was obtained for the study (Biomedical Research 
Ethics Committee, University of KwaZulu-Natal, South Africa; reference number BE 119/11). After 
informed consent was obtained, participants were recruited over a 14 month period from July 2013 to 
September 2014 from the maternity unit at Prince Mshiyeni Memorial Hospital in Durban, South Africa. 
This hospital is a regional level facility and serves a predominantly semi–urban African population from 
where the participants were recruited.  Normotensive (n=95, age range: 16-46 years) and PE patients 
(n= 98, age range: 16-42 years) were enrolled into the study. Maternal venous blood samples were then 
taken. To maintain ethnographic and anthropometric consistency, all patients recruited were of African 
descent, resident in the same geographical location and of Zulu ethnicity. All patients were non-
smokers, non-consumers of alcohol or recreational drugs, and all HIV infected patients were on 
HAART (tenofovir, emtricitabine, efavirenz) as per the National guidelines (NDH 2013). Calcium 
supplementation was administered routinely to all patients attending the clinic. Women with gestational 
hypertension, renal disease, diabetes mellitus, chronic hypertension and collagen vascular disease were 
excluded. Preeclampsia was defined as a blood pressure ≥ 140mmHg systolic or ≥ to 90 mmHg diastolic 
on 2 occasions at least  4 hours apart after 20 weeks of gestation in a woman with previously normal 
blood pressure (Roberts, August et al. 2013). All patients had proteinuria ≥ +1 on urine dipstick testing. 
Data on all patients was obtained from the institution’s maternity case records and laboratory data from 
the National Health Laboratory Services computerised database at the institution, and HIV was 
diagnosed on a rapid test kit. Weight was categorised as: normal weight (BMI: 18-<25), overweight 
(BMI: 25-<30) and obese (BMI: 30+). A summary of the clinical characteristics of the participants is 
shown in Table 1. 
 
Cytokine quantification: 
The BD Cytometric Bead Array Human Th1/Th2/Th17 Cytokine kit was used to measure the IL-2, 
TNF-α, IFN-γ and IL-6, protein levels in a serum samples. Briefly, lyophilized standards were prepared 
by reconstitution and serial dilution (1:2 – 1:256) in assay diluent immediately before staining with 
Capture Beads and PE Detection Reagent. All serum samples were also diluted in assay diluent (1:4) 
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before staining with Capture Beads and PE Detection Reagent. For the staining procedure, 50μL of each 
standard and unknown sample was added to appropriately labeled sample tubes followed by 50μL of 
the Human Th1/Th2/Th17 PE Detection Reagent and incubated (3 h, RT, protected from light). 
Following incubation 1 mL of Wash Buffer was added to each assay tube and centrifuged at 200xg for 
5 minutes. The supernatant from each assay tube was then carefully aspirated and 300μL of Wash Buffer 
was added to each assay tube to resuspend the bead pellet. Flow cytometric data was acquired using the 
BD AccuriC6 Sampler counting 2100 gated events. This ensures that the sample file contains 
approximately 300 events per Capture Bead. Data analysis was performed using the FCAP Array 
analysis software. All cytokines are represented as pg/mL as extrapolated from standard curves.  
 
Statistical analysis 
Statistical analysis was done using SPSS® version 22. Correlation between continuous variables was 
assessed using the Spearman rank correlation coefficient. The Wilcoxon rank-sum (Mann-Whitney) test 
was used to compare difference in sum of ranks (i.e. cytokine concentration) by dichotomous group, 
mainly between PE HIV− and PE HIV+. Comparisons of mean across 3 or more groups were done 
using the Kruskal–Wallis test. Non-parametric approaches were employed above as cytokine 
distributions were not normally distributed with evidence of asymmetry. The Pearson Chi-square (χ2) 
test was used to test association between group(s) and categorical explanatory variables. In the 
determination of significance, a p-value < 0.05 was deemed statistically significant.  
 
Results: 
The clinical characteristics of participants are shown in Table 3.1. The average duration of HAART 
was 16.6 weeks in the control group and 14.5 weeks in the preeclamptic group, however the duration 
of exposure is not accurate. All women were in the third trimester of pregnancy and the mean gestational 
age was 36.5 weeks of gestation.  There was a significant difference in the parity across all groups 











Table 3.1. Clinical characteristics of participants 
 
Variable  PE HIV  
uninfected 
(Grp 1) 








  uninfected 
    ( Grp 3) 
      n=50 
Normotensive 
HIV infected 
    (Grp 4) 
       n=45 
 Total 





p value  
(Grp 1 
vs 2) 
Age (yrs)(n,%)  















28 ± 6.4 
17-46 
192(99) 0.002 0.003 
Parity  
(n, %  )  












  1 (25.0) 
 
 
 17(25.8)   
 31(25.2) 









  66 (34) 
 123(64) 
      4 (2) 
0.006 
 
















































































    9(17) 
  32(60) 



























  70(37) 
  79(42) 








Abbreviations: GA = gestational age, BMI = Body Mass Index, MOD= mode of delivery, ELCS= elective caesarean section, 
EMCS= emergency caesarean section, VD= vaginal delivery, SD=standard deviation PE=preeclampsia, n=total number (1): 




There was also a significant difference in age across the groups, however there was little or no 
correlation between cytokine levels and age i.e. suggesting little confounding influence of age in this 
regard. Hence age was not factored into the cytokine comparison by group. The overall quantitative 
evaluation of cytokines and group sub-analysis is shown in Table 3.2 and 3.3 and Fig.3.1and 3.2 
respectively. Significant differences were found in many of the circulating cytokines investigated. In 
the control groups i.e. normotensive groups, significant decreases were found in IL-2 (p=0.010), TNF-
α (p=0.045), and IL-6 (p=0.005), and a non-significant decrease in IFN-ɣ (p=0.345) in HIV infected 
women on HAART {4} compared to uninfected controls {3}. 
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PE+HIV+ {2}       




PE- HIV- {3}            
         vs  
PE +HIV- {1} 
 
 
PE – HIV+ {4}        
       vs 
PE – HIV- {3} 
     
     
(1) IL2 
(pg/ml) 
p-value i 0.0008 0.9384 0.0104 
Group { } 
Median [ ] 
(IQR) 








{1}   [273.2]      
(269.5,278.6) 










p-value i 0.0001 0.2792 0.0453 
Group { } 
Median [ ] 
(IQR) 
{2}  [172.2] 
(161.2,181.3) 




{1}  [185.2] 
(178.7,196.2) 






p-value i 0.0233 0.5534 0.3451 
Group { } 
Median [ ] 
(IQR) 
{2}  [214.1] 
(205.1,218.3) 




{1}  [218.3] 
(208.7,226.1) 






p-value i 0.0865 0.7743 0.0051 
Group { } 
Median [ ] 
(IQR) 
{2}   [139.7] 
(131.8,163.2) 




{1}  [147.0] 
(138.4,173) 




Abbreviations: PE= preeclampsia, HIV = Human Immunodeficiency Virus,  
IL-2 = interleukin 2, TNFa=tumour necrosis factor alpha, IFNg=interferon gamma, 
 i: Wilcoxon rank-sum (Mann-Whitney) test, IQR: interquartile range, vs=versus 
 
In the experimental group i.e. preeclamptic women, significant decreases were observed in IL-2 and 
TNF-α (p=0.000; p=0.000) and non-significant decreases in IFN-ɣ and IL-6 (p=0.023; p=0.086) in 
HIV infected women on HAART {2} compared with uninfected preeclamptic women {1}.  No significant 
differences were observed in uninfected preeclamptic women {1} when compared with uninfected 











Table 3.3: Comparative analysis of cytokine perturbations by groups    
CYTOKINE    HIV+ vs  HIV - 
  ( Group 4 vs 3 ) 
( Δ in median pg/ml) 
(p value in brackets) 
PE vs NORMOTENSIVE  
    ( Group 1 vs 3 ) 
  (Δ in median pg/ml) 
   (p value in brackets) 
PE/ HIV+ vs PE/ HIV -  
      ( Group 2 vs 1 )  
(Δ  in median pg/ml) 
( p value in brackets ) 
IL2    -16.8     (0.010)*     -1.20     (0.938)   -4.5      (0.000)*  
TNFα    -24.0     (0.045)*     -13.60    (0.279)     -13.0    (0.000)*  
IFNɣ    -3.0       (0.345)     +1.20    (0.553)    -4.2      (0.023) 
IL6    -16.8     (0.005)*     -2.80     (0.774)   -7.3      (0.086)     
*(p> 0.05 is deemed statistically significant);   Δ = difference in values; PE= preeclampsia  
 
 
The relationship between cytokine estimations in the respective groups are depicted in Figures 3.1 and 
3.2 below. Differences in concentrations and spread of the cytokines shown in Table 3.2 can be 
graphically observed in Figure 3.2.                                                                      
 
Figure 3.1: Relationship between individual cytokine            Figure 3.2: Cytokine concentrations by      
concentration                                                                          group comparison 
                                                                                                                         
 
Discussion: 
Our study demonstrates that decreases in inflammatory cytokines occur in association with HAART in 
normotensive pregnancies and in preeclampsia.  HAART may have an attenuating effect on the pro-
inflammatory environment generally associated with preeclampsia (Saito, Umekage et al. 1999, Bates 
, Quenby et al. 2002 , Cemgil Arikan, Aral et al. 2012), similar to that occurring in normotensive 
women, and may inhibit the pro-inflammatory sequelae of preeclampsia.  
 Cytokines have been implicated as potential mediators in preeclampsia, where endothelial dysfunction 
is considered the hallmark of the syndrome (Szarka, Rigó et al. 2010) . Cytokines may also be involved 




























































maternal blood in preeclampsia. (Raghupathy 2013). The alteration between pro-
inflammatory/regulatory responses does not occur in preeclampsia, or may be reverted in very early 
stages of the disease, leading to a pro-inflammatory state (Pinheiro, Martins-Filho et al. 2013). In our 
study, we did not find significant differences in IL-2, TNF-α, IFN-ɣ or IL-6 in pre-eclamptic women 
compared to normotensive women. Our findings do not reflect the pro-inflammatory environment in 
PE shown in other studies (Saito, Umekage et al. 1999, Bates , Quenby et al. 2002 , Cemgil Arikan, 
Aral et al. 2012), however differences in study designs exist in relation to  sample population , 
pregnancy status,  and sampling techniques. 
 
HIV is known to infect T cells that have CD4+ receptors present on their surface, which, among others 
in the immune system, secrete cytokines (Tudela, Singh et al. 2014). Studies conducted earlier have 
revealed that HIV-infected individuals have a weaker immune system and the inability of CD4+ T cells 
to proliferate, due to the decrease in the levels of IL-12 (Noble, Thomas et al. 2001). As a result, 
decreases in IL-2 and IFN-γ occur, leading to immunosuppressive effects and opportunistic infections, 
a marker of advanced disease. In a recent study of the cytokine milieu in untreated HIV infection, pro-
inflammatory cytokines, IL-2, IL-12, and IFN-γ were shown to be significantly decreased. CD4 cell 
counts are an important biomarker for HIV progression, and are  lower in HIV participants versus 
healthy participants (Tudela, Singh et al. 2014). In our study, we did not find a significant difference 
between the CD4+ counts in normotensive HIV infected women and those with preeclampsia, however, 
both groups were on HAART in terms of existing guidelines (NDH 2013).  
 
Because HIV has immune – depressive effects, an association between preeclampsia and HIV has been 
suggested (Hall, Gebhardt et al. 2014). Highly active antiretroviral therapy (HAART) suppresses HIV 
viremia, increases CD4+ cell counts and is suggested to counteract the Th1 to Th2 shift in the disease 
progression of HIV (Fiore, Newell et al. 2006). Its use in pregnancy provides significant benefits in 
delaying HIV disease progression and reducing the risk of mother-to-child-transmission, and has been 
integrated into policy (NDH 2013).  
 
Our data shows significant decreases in the pro-inflammatory cytokines IL-2 (p=0.010), TNF-α 
(p=0.045), and IL6 (p=0.005), and a non-significant decrease in IFN-ɣ (p=0.345) among HIV positive 
normotensive women on HAART compared with uninfected normotensive pregnant women, 
highlighting the suppressive effect of HAART on these inflammatory cytokines. A similar significant 
effect on IL-2 and TNF-α (p=0.000; p=0.000) and non-significant decreases in IFN-ɣ and IL-6 
(p=0.023; p=0.086) was observed with HAART in HIV infected preeclamptic women when compared 
to uninfected preeclamptic women, suggesting a potentially attenuating effect of HAART on 
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inflammatory cytokines in uncomplicated and preeclamptic HIV infected pregnancies. . Similar 
findings were observed in a local study among Black African participants, receiving HAART, although 
this study involved non –pregnant participants (Malherbe, Steel et al. 2014). Our data suggests that 
immune reconstitution by HAART in these conditions includes alterations in pro-inflammatory 
cytokines. Although some clinical data is associated with a lower rate of preeclampsia among HIV 
positive women who receive HAART (Mattar, Amed et al. 2007), further randomised control trials are 
necessary to determine the clinical association. Currently there is a paucity of data on cytokine mediated  
immune reconstitution effects associated with HAART in pregnancy, possibly due to differences in 
drug regimens ,patient profiles, study  settings and rapidly evolving therapeutic regimens.  
 
Our study was limited by the lack of knowledge on the precise duration of HAART, and detailed 
knowledge of drug adherence. Moreover, pregnancy is inherently immunogenic and is associated with 
longitudinal variation, posing further challenges to accurately contextualise changes. In our study, we 
did not include patients with untreated HIV infection, which is unethical under the current guidelines. 
Our study was conducted among African women, and, therefore, the results may not be generalizable 
to other HIV-infected populations. In the context of racial variation on cytokine responses, African–
Americans have been shown to have  higher baseline levels of inflammatory cytokines (Slopen, Lewis 
et al. 2010). Differences in sample sizes, patient selection and techniques used, further contribute to 
heterogeneity among studies relating to preeclampsia and HIV.  Furthermore, functional pleiotropy and 
redundancy are characteristic features of cytokines, and may show overlapping activities depending on 
the type and developmental state of the target cells involved (Scheller, Chalaris et al. 2011). 
 
Conclusion:  
The effects of HAART in pregnancy include alterations in pro-inflammatory cytokines IL-2, TNF-α, 
IFN-ɣ and IL-6.  In uncomplicated/ normotensive pregnancies, HIV/HAART was associated with 
significant reductions in IL-2, TNF-α and IL-6. In pre-eclampsia, HIV/HAART was associated with 
significant decreases in IL-2 and TNF-α. These findings highlight the need for further investigation on 
the immune reconstitution effects of HAART during pregnancy, and the potential of immune 
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Synopsis: MiR-27a rs895819 polymorphism may not be associated with increased susceptibility to 
preeclampsia (PE); however, the miR-27a TC/CC genotype increases susceptibility to elevated BMI in 
PE, which may be significantly influenced by Human Immunodeficiency virus (HIV) infection and 
















Preeclampsia (PE) and HIV/AIDS present a major health challenge globally. South Africa has the 
highest disease burden of both HIV/AIDS and PE in the world. Despite extensive research, the 
pathophysiology of these conditions is not completely understood, however a genetic predisposition in 
women may affect susceptibility. MiRNA-27a regulates adipogenesis and glucose metabolism.  A 
single nucleotide polymorphism (SNP) in miRNA-27a (rs895819T>C) has shown to have disparate 
effects in various populations.  This study investigated the frequency of rs rs895819T>C in pregnant 
normotensive and preeclamptic Black South African women.  The cohort was genotyped and the 
association of the SNP to PE in the presence of co-morbid HIV infection treated with HAART was 
determined. 
Enrollment into the study included: normotensive (n=95; 80 analysed for rs895819T>C, age range: 16-
46 years) and PE patients (n= 98; 56 analysed for rs895819T>C), age range: 16-42 years). DNA was 
isolated from peripheral blood mononuclear cells (PBMCs). Genotyping and the polymorphism of 
miRNA-27a (rs895819) was detected using a TaqMan® SNP Genotyping assay.  The cytokines 
Interleukin-2 (IL-2), Tumor Necrosis Factor (TNF)-α, Interferon-γ (IFN-γ) and Interleukin-6 (IL-6) 
were measured using the BD Cytometric Bead Array Human Th1/Th2/Th17 Cytokine kit. All other 
clinical parameters were obtained from institutional records. We did not find a significant association 
of miR-27a polymorphism with PE susceptibility in our data. However, in the subgroup analysis, the 
variant genotypes (TC/CC) were associated with higher body mass index (BMI) among PE women 
(32.57 vs 29.25, p=0.064), significantly in the presence of HIV infection (33.47 vs 27.8, p=0.005).  The 
results of this  study suggests that miR-27a rs895819 may not be associated with PE susceptibility; 
however, the miR-27a TC/CC genotype increases susceptibility to elevated BMI in PE, which may be 
significantly influenced by co-morbid HIV infection among pregnant women on HAART.  
 
Keywords: miR-27a, preeclampsia, Black South African women, single nucleotide polymorphism, 













Preeclampsia (PE) is a pregnancy-specific multi-organ syndrome recognized by the new onset of 
hypertension and proteinuria after 20 weeks of gestation (Jeyabalan, 2013). Globally, PE complicates 
approximately 2-10 % of pregnancies and is associated with 10-15% of direct maternal deaths overall 
(Duley, 2009). Perinatal complications include premature delivery, intra-uterine growth restriction, 
hypoxic neurological lesions and foetal death (Lorquet et al., 2010). The overall risk of PE is further 
increased by obesity (Bodnar et al., 2005) and features of the metabolic syndrome (obesity, 
hypertension, insulin resistance, impaired glucose tolerance, and dyslipidaemia) occur more commonly 
in women with PE (Kaaja, 1998). Furthermore, PE has also been associated with cardiovascular disease 
in later life (Gynecologists, 2013). 
 
The pathogenic mechanisms underlying PE remain to be elucidated; however, immune maladaptation, 
inadequate placental development and trophoblast invasion, placental ischaemia, oxidative stress and 
thrombosis are all thought to represent key factors in the development of disease (Williams and Pipkin, 
2011 ). All of these components have genetic factors that may be involved in the pathogenesis of PE  
(Williams and Pipkin, 2011). 
 
MicroRNAs (miRNAs) are endogenous small RNAs that post transcriptionally regulate gene expression 
and have been shown to have important roles in numerous disease processes (Hilton et al., 2013). 
Interestingly, many miRNA regulated pathways are co-incident with pathophysiological processes 
related to PE. For instance, miRNAs regulate pathways in adipose tissue that control adipogenesis, 
insulin resistance and inflammation (Hilton et al., 2013), and regulate endothelial cell function and 
angiogenesis by regulating pro- and anti-angiogenic activity (Urbich et al., 2012). They have also been 
shown to regulate vascular integrity in angiogenesis induced by ischemia (Fish et al., 2008; Solingen et 
al., 2009).  
 
More specifically, evidence shows  the involvement of miRNA-27a (miR-27a), a member of the miR-
23∼27∼24 cluster (Zhu and Fan, 2013), in the regulation of many of these processes. MiR-27a promotes 
angiogenesis by targeting the angiogenesis inhibitor SEMA6A, which controls repulsion of 
neighbouring endothelial cells (Urbich et al., 2012). It plays an anti-adipogenic role by influencing 
prohibitin and impairing mitochondrial function (Kang et al., 2013) and in cardiovascular disease, it is 
associated with angiogenesis and endothelial apoptosis in cardiac ischemia (Bang et al., 2012).  Its role 
in inflammation is demonstrated by enhanced expression of pro-inflammatory cytokines, such as IL-10 
when up-regulated in Tlr2- or Tlr4-activated macrophages (N Xie et al., 2014). More recently, a knock 
down of miR-27a, has been shown to down regulate pro-inflammatory cytokines IL-6 and TNF-α, 
which are associated with PE (Wang et al., 2014) (Martínez-Varea et al., 2014). 
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Genetic polymorphisms involve one of two or more variants of a particular DNA sequence and can  
affect miRNA expression, maturation or mRNA recognition and may represent an important risk 
determinant of disease susceptibility (Li et al., 2015). The miR-27a single nucleotide polymorphism 
(SNP) rs895819 is located in the terminal loop of pre-miR-27a  (Shi et al., 2012). Given the biological 
functions associated with miR-27a and the role of the SNP rs 895819 in the promotion of cell growth 
and proliferation (Stenholm et al., 2013), this study investigated the association of rs 895819 with PE, 
related clinical features and cytokines among Black South Africa women, where the prevalence of PE 
is very high (Moodley and Kalane, 2006).  Due to the associated high rate of co-morbid HIV infection 
in this population (HealthSystemsTrust, 2012) we included HIV infected women on HAART to identify 
differential associations.  
 
 
2. Materials and Methods 
 
2.1. Study population and sample collection 
 
Institutional ethical and hospital regulatory permission was obtained for the study (Biomedical Research 
Ethics Committee, University of KwaZulu-Natal, South Africa; reference number BE 119/11). After 
informed consent was obtained, participants were recruited over a 14 month period from July 2013 to 
September 2014 from the maternity unit at Prince Mshiyeni Memorial Hospital in Durban, South Africa. 
This hospital is a regional level facility and serves a predominantly semi–urban African population from 
where the participants were recruited.  Normotensive [n=95, (80 analysed for rs895819T>C), age range: 
16-46 years] and PE patients [n= 98 (56 analysed for rs895819T>C), age range: 16-42 years] were 
enrolled into the study. Maternal venous blood samples were then taken. To maintain ethnographic and 
anthropometric consistency, all patients recruited were of African descent, resident in the same 
geographical location and of Zulu ethnicity. All patients were non-smokers, non-consumers of alcohol 
or recreational drugs, and all HIV infected patients were on highly active antiretroviral therapy ( 
HAART viz. tenofovir, emtricitabine, efavirenz) as per the National guidelines (NDoH, 2013). Calcium 
supplementation was administered routinely to all patients attending the clinic. Women with gestational 
hypertension, renal disease, diabetes mellitus, chronic hypertension and collagen vascular disease were 
excluded. PE was defined as a blood pressure ≥ 140mmHg systolic or ≥ to 90 mmHg diastolic on 2 
occasions at least  4 hours apart after 20 weeks of gestation in a woman with previously normal blood 
pressure (Gynecologists, 2013). All patients had proteinuria ≥ +1 on urine dipstick testing. Data on all 
patients was obtained from the institution’s maternity case records and laboratory data from the National 
Health Laboratory Services® computerised database at the institution. HIV was diagnosed on a rapid 
test kit, Weight was categorised as: normal weight (BMI: 18-<25), overweight (BMI: 25-<35). Early 
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onset preeclampsia was considered as ≤ 34 weeks of gestation (Tranquilli , 2014). Severe preeclaampsia 
was diagnosed when features included any of the following: systolic blood pressure ≥160 mmHg or 
diastolic blood pressure ≥110 mmHg; maternal neurological disorders such as persistent headaches and 
brisk reflexes, eclampsia, acute pulmonary edema, proteinuria ≥5 g/day, oliguria <500 cc/day, 
creatinine >120 μmol/L, features HELLP syndrome and thrombocytopenia <100,000/mm3, fetal criteria 
including intrauterine growth retardation, oligohydramnios, or fetal death in utero. (Obstetricians and 
Gynecologists 2013), (Sibai, Dekker et al. 2005) .    
 
2.2    DNA Extraction & Genotyping  
DNA from PBMCs of 56 PE patients and 80 normotensive subjects was extracted using the Quick-
gDNA MiniPrep kit (Zymo Research, catalogue no. D3006) and FlexiGene DNA kit (Qiagen, catalogue 
no. 51204) as per the manufacturer’s protocol. DNA was quantified using the Nanodrop2000 
spectrophotometer. All samples were standardised to a concentration of 10ng/μL. 
 
All subjects were genotyped for miR-27a rs895819 using a TaqMan® Pre-designed SNP genotyping 
assay (Life Technologies, catalogue no. 4351379), following the manufacturer’s protocol. A final 
reaction mixture consisted of 40× TaqMan® Predesigned genotyping assay, 2×TaqMan® Genotyping 
Master Mix, nuclease-free water, and a 10ng genomic DNA template. The experiment was performed 
using the Applied Biosystems® ViiA™ 7 Real-Time PCR System. 
 
The TaqMan Predesigned Genotyping Assay contains two primers for amplifying the sequence of 
interest, and two TaqMan® minor-groove binding (MGB) probes for detecting alleles. The presence of 
two probe pairs in each reaction allows genotyping of the two possible alleles at the SNP site in a DNA 
target sequence. The genotyping assay determines the presence or absence of a SNP based on the change 
in fluorescence of the dyes associated with the probes. Each probe is labelled with a VIC® dye-labelled 
probe and FAM™ dye-labelled probe - assigned specifically to either the ancestral or variant allele. 
 
2.3. Cytokine quantification: 
 
The BD Cytometric Bead Array Human Th1/Th2/Th17 Cytokine kit was used to measure the 
Interleukin (IL)-2, IL-6, IL-4, IL10, IL 17a, Tumour Necrosis Factor (TNF)-α and Interferon-γ (IFN-γ) 
levels in each patient serum sample. Briefly, lyophilized standards were prepared by reconstitution and 
serial dilution (1:2 – 1:256) in assay diluent immediately before staining with Capture Beads and PE 
Detection Reagent. All serum samples were also diluted in assay diluent (1:4) before staining with 
Capture Beads and PE Detection Reagent. For the staining procedure, 50μL of each standard and 
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unknown sample was added to appropriately labelled sample tubes followed by 50μL of the Human 
Th1/Th2/Th17 PE Detection Reagent and incubated (3h, RT, protected from light). Following 
incubation 1mL of Wash Buffer was added to each assay tube and centrifuged at 200g for 5 minutes. 
The supernatant from each assay tube was then carefully aspirated and 300μL of Wash Buffer was 
added to each assay tube to resuspend the bead pellet. Flow cytometric data was acquired using the BD 
AccuriC6 Sampler counting 2100 gated events. This ensured that the sample file contained 
approximately 300 events per Capture Bead. Data analysis was performed using the FCAP Array 
analysis software. All cytokines are represented as pg/mL as extrapolated from standard curves.  
 
2.4 Statistical analysis:  
 
Statistical analyses were done using GraphPad prism software (version 5.0). The Hardy–Weinberg 
equilibrium was used to test for deviation of allele/genotype frequency. Allele and genotype frequencies 
were calculated using the Fisher’s exact and Chi square tests, respectively, and the Odd’s ratio and 
confidence intervals were determined. To assess difference in the clinical parameters (not grouped 
according to genotype), the t-test with Welch’s correction or one-way ANOVA tests were used. The 
correlations between the clinical parameters, grouped per genotype, were assessed for PE and 
normotensive patients, which were also further tested under the HIV positive and negative subsets. The 
t-test with Welch’s correction and Fisher’s exact test were used for these analyses. A p-value <0.05 was 




The clinical characteristics of all study subjects are shown in Table 4.1. The study cohort was 
categorised into 4 groups: (1) uninfected PE women (PEHIV-), (2) infected PE women (PEHIV+), (3) 
uninfected normotensive women (Normo-) and (4) infected normotensive women (Normo+). All 
women were in the third trimester of pregnancy and the mean gestational age was 36.5 weeks. There 
was a significant difference in the parity across all groups but not between the PE women (p=0.400). 
There was also a significant difference in age across the groups, however there was little or no 
correlation between cytokine levels.  The average duration of HAART was 16.6 and 14.5 weeks in the 
normotensive and PE groups respectively, however this is not a precise duration of exposure. There 
were significant differences in the mode of delivery, based on obstetric related indications. CD4 counts 







Table 4.1: Clinical characteristics of participants: 
Variable      PE HIV-  
(n= 53)  
 
PE HIV+ 
( n=45)  
 
NORMO 
  HIV- 
 (n=50) 
NORMO 
  HIV + 
  (n=45) 
 Total 
   
(n=193) 




p value   
PE HIV- 
     vs 
PE 
HIV+ 
Age (n, %)            
















28 ± 6.4 
17-46 
192(99) 0.002 0.003 
Parity  
(n, %  )  




























   4 (100) 
0.006 
 





















 0.399* --- 
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145(76) 





















































Abbreviations: GA = gestational age, BMI = Body Mass Index, MOD= mode of delivery, ELCS= 
elective caesarean section, EMCS= emergency caesarean section, NVD= normal vaginal delivery, 
SD=standard deviation PE=preeclampsia, NORMO=normotensive, n=total number (1): p = 




The genotype and allele frequencies of the ancestral TT, heterozygous TC and homozygous CC variants 
are shown in Table 4.2. There was no significant difference in the genotype or T/C allele frequencies 
when compared between all normotensives and all PE women (p= 0.834, p=0.806). The genotype 




Table 4.2: miR-27a genotype and allele frequency distribution in controls and pre- eclamptic 
patients 
 †Normotensive 
 (n = 80) 
‡Preeclamptic  
(n = 56) 
p-value (Odds ratio; 
95% CI) 
Genotypes n (%)    
TT  18 (23) 13 (23) 0.834 
TC  41 (51) 26 (46) 
CC  21 (26) 17 (31) 
Alleles n (%)   0.806 (0.9342; 0.5758 
- 1.516) T 77 (48) 52 (46) 
C 83 (52) 60 (54) 
HWE p-value 0.972 0.882 
Abbreviations: HWE = Hardy Weinburg Equilibrium; CI =confidence interval; †= all cases; ‡=all 
cases; p<0.05 is statistically significant; T=thymine, C= cytosine  
 
 
Table 4.3 represents a sub-analysis of the genotype and allele frequencies among women stratified 
according to HIV status (i.e. negative or positive).  No significant differences were noted in the genotype 
or allele frequencies among all groups. No significant differences were noted between groups (p= 0.834; 












Table 4.3: Genotype and allele frequencies between groups 
 Norm HIV 
negative 
 (n = 42) 
Norm HIV  
positive  
(n = 38) 
PE HIV  
negative 
(n = 29) 
PE HIV  
positive 
(n = 27) 
Genotypes n (%)     
TT  8 (19) 10 (26)  8 (28)  5 (19) 
TC 23 (55) 18 (48) 11 (38) 15 (56) 
CC 11 (26) 10 (26) 10 (34)  7 (25) 
Alleles n (%)     
T 39 (46) 38 (50) 27 (47) 25 (46) 
C 45 (54) 38 (50) 31 (53) 29 (54) 
HWE 0.8076 0.9487 0.4405 0.8306 
 Genotypes  
p-values 
Alleles 
 p-values (OR; CI) 
  
All groups 0.8338 0.9636   
PE HIV- vs PE 
HIV+ 
0.4131 1.000 (0.9898; 
0.4707 - 2.082) 
  
Norm HIV- vs 
Norm HIV+ 
0.7113 0.7515 (1.154; 
0.6198 - 2.148) 
  
Norm HIV- vs PE 
HIV- 
0.3737 1.0000 (1.005; 
0.5137 - 1.966) 
  
Norm HIV + vs 
PE HIV + 
0.7316 0.7238 (0.8621; 
0.4285 - 1.734) 
  
Abbreviations: PE= preeclampsia; norm+ normotensive; HWE= Hardy Weinburg Equilibrium; 
p<0.05 is statistically significant  
 
 
Table 4.4 represents the association between the ancestral and variant genotypes with clinical features 
in all (a) PE women, and (b) according to HIV status.  Correlations were made  with respect to  mean 
concentrations of cytokines TNF-α, IFN-ɣ , and IL-2, IL-17a, IL-6, IL-10 and IL-4, in HIV infected 
and uninfected women with PE relating  to the genotypes, however no significant differences were 
found between the  groups.   Of note was the significant association of the variant genotype (TC/CC) 
with body mass index (BMI) in the PE HIV+ group (27.8 ± 0.69 vs 33.47 ± 1.66; p=0.0059).  Moreover, 
a similar but non-significant trend of higher BMI values were also noted among PE HIV- women (29.5 
± 1.45 vs 31.7 ± 2.11; p=0.388), and among all PE women overall (29.2 vs 32.6, p=0.064), in association 




Table 4.4. Association of rs895819T/C genotypes with clinical parameters in preeclampsia and 
HIV co-infection  
 (a)                                                            PREECLAMPSIA  (n=56) 
Variable                     TT vs TC/CC p-value 
BMI (kg/m2)  29.25 ± 1.084 vs 32.57 ± 1.344  0.0643 
Age (years)  25.85 ± 2.186 vs 27.28 ± 1.045  0.5621 
CD4 ( x 106/l)  446.0 ± 110.9 vs 471.9 ± 37.00  0.8357 
EOPE (%)  31 vs 72 0.5346 
Severe PE(5)  38 vs 49 0.5453 
No of AHT drugs   1.692 ± 0.2371 vs 1.595 ± 0.1081  0.7141 
SYS BP(mmHg)  154.5 ± 3.890 vs 160.8 ± 2.342  0.1810 
DIA BP(mmHg) 
 
 100.0 ± 2.614 vs 105.0 ± 1.692  0.1268 
(b)       PE HIV-  (n=29)        PE HIV+ ( n=27) 
Variable         TT vs TC/CC p-value         TT vs TC/CC p-value 
BMI  29.5 ± 1.45 vs 31.7 ± 2.11  0.3882 27.8 ± 0.69 vs 33.47 ± 1.66 0.0059* 
Age  24.00 ± 2.18 vs 25.4 ± 
1.11  
0.5736 28.8 ± 4.51 vs 29.05 ± 
1.682  
0.9613 
CD4  N/A N/A 446  ± 110.9 vs 453  ± 36.4  0.9551 
EOPE (%) 25 vs 29 1.000 40 vs 55 0.6483 
Severe PE (%) 38 vs 27 1.000 40 vs 59 0.6280 
No of AHT drugs  2.0 ± 0.32 vs 1.40 ± 0.112  0.1212 1.20 ± 0.200 vs 1.77 ± 
0.173 
0.0533 
SYS BP(mmHg) 153 ± 5.91 vs 161.7 ± 5.1  0.2946 156 ± 4.986 vs 163 ± 3.224  0.2764 
DIABP (mmHg) 99 ± 3.51 vs 102 ± 2.38 0.5116 102 ± 4.250 vs 108 ± 2.274 0.2507 
Abbreviations: BMI =body mass index, EOPE= early onset preeclampsia, PE=preeclampsia; 
AHT=antihypertensive drugs; SYS/DIA BP= systolic and diastolic blood pressure;  
 
Table 4.5 shows a sub-analysis of the BMI in all the groups. Among normal pregnancies 
(normotensive), the variant genotype was associated with a significantly lower BMI (29.0 vs 34.3, p= 
0.047), which appears unaffected by HIV infection. In contrast, the variant genotype was associated 
with a higher BMI among all women with PE (p= 0.064). This however, was significantly higher in PE 
women with co-morbid HIV infection on HAART (p= 0.005). Due to policy guidelines, a cohort of 





Table 4.5: Sub-analysis of Body Mass Index and rs895819 genotypes in all groups  
Groups TT                  vs     TC/CC BMI Trend  P value  
All PE 29.25 ± 1.084 vs 32.57 ± 1.344  0.0643 
PE HIV - 29.50 ± 1.458 vs 31.77 ± 2.111  0.3882 
PE HIV+ 27.87 ± 0.6960 vs 33.47 ± 1.666  0.0059* 
All NORMO 34.31 ± 2.258 vs 29.03 ± 1.019         0.0473* 
NORMO 
HIV- 
32.14 ± 2.512 vs 29.48 ± 1.535      0.3971 
NORMO 
HIV+ 
35.51 ± 3.260 vs 28.56 ± 1.359  0.0774 




Figures 4.1 and 4.2 show a graphic analysis of BMI grouped per genotype for all PE patients. The mean 
BMI in the ancestral group is 29.25 ± 1.084 compared with 32.57 ± 1.344 in the variant types, 
demonstrating the elevated BMI associated with the variant genotype.  This observation is in contrast 
to that observed in the normotensive women that showed a lower BMI in relation to the variant genotype 
(TT: 34.31 ± 2.258; TC/CC:  29.03 ± 1.019).  
                                                                                                                                                                                     
   
Figure 4.1. BMI per genotype for all PE women                     Figure 4.2: BMI per genotype for all    
                                                                                                             normotensive women        
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Figures 4.3 and 4.4 demonstrate the BMI and genotype relationship in PE women with and without co-
morbid HIV infection. There is a significant difference in the HIV infected PE group compared with 
the HIV uninfected group which shows a non-significant increase (27.87 ± 0.6960 vs 33.47 ± 1.666; p= 
0.0059*vs. 29.50 ± 1.458 vs 31.77 ± 2.111; p= 0.3882). Figure 4.5 represents the overall BMI grouped 
per genotype for all subjects in the cohort.  
                      
                                                                        
Figure 4.3. BMI per genotype in PE HIV+ women                      Figure 4.4. BMI per genotype in           
                                                                                                                    PE HIV- women 
 
                                                                                                                                                                                                            
 
                  Figure 4.5 BMI’s grouped per genotype for all subjects 
 




Figure 4.6 shows the divergent association of the variant genotype with normotensive, PE and HIV 
infected PE women.  In pregnant women with the variant genotype, the BMI is lower in the 
normotensive groups, but rises in the PE group. The BMI in this group specifically, is significantly 
higher in the presence of HIV/HAART (27.87 ± 0.69 vs 33.47 ± 1.66; p= 0.0059).  This trend is 
diametrically opposed to the group of women with the ancestral genotype, who had a higher BMI in 
normotensive groups, but lower BMI with PE, lowered further by the presence of co-morbid HIV 
infection.  
                                   
                              Figure 4.6: BMI’s in different genotypes in all groups  
 
4. Discussion   
 
The morbidity and mortality associated with PE and HIV/AIDS remains a global health concern. In 
developing countries, and South Africa in particular, hypertensive disorders of pregnancy and 
HIV/AIDS have remained leading causes of mortality despite sustained interventions (NCCEMD, 
2011-2013). Existing research aimed at better understanding the pathophysiology of PE and the 
associated complications still remains inconclusive. Contemporary and new studies now extend to 
include both genetic and epigenetic aspects of PE.  
 
In this study, the findings do not show significant differences in the ancestral and variant genotype and 
allele frequencies among the groups and in relation to the parameters described. However, of relevance 
is the observation that the variant TC/CC genotype is associated with higher BMI in the PE women 
studied (TT: 29.25 ± 1.084 vs TC/CC: 32.57 ± 1.344, p= 0.06), in contrast to lower BMI values in 
normotensive pregnancies (TT: 34.31 ± 2.258 vs TC/CC: 29.03 ± 1.019 p=0.04). In the normotensive 
women, the presence of HIV infection is associated with a decrease in BMI in the variant group, 
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however in PE, it is associated with a significant increase among carriers of the variant genotypes (TT: 
27.87 ± 0.6960 vs TC/CC: 33.47 ± 1.666, p=0.005). A relationship of susceptibility to increased BMI 
may therefore exists in women with PE who carry the variant genotypes. This relationship may be 
further potentiated by the presence of co-morbid HIV infection (on HAART), through complex 
differential regulation of miR-27a.  
 
The regulatory activity of miR-27a has also been associated with viral infections. Buck et al. (2010) 
observed that both host and virus contain mechanisms to regulate miRNA expression and/or activity 
(Buck et al., 2010). As the expression of miR-27a is associated with reduced adipogenesis, the variant 
genotype may be associated with dysregulation in PE, which is possibly further potentiated by co-
existing HIV disease through complex mechanisms. 
 
The regulatory activity of miR-27a in adipogenesis has been demonstrated previously (Lin et al., 2009) 
- the overexpression of miR-27a specifically inhibited adipocyte formation, and expression of miR-27a 
results in blockade of expression of peroxisome proliferator-activated receptor gamma (PPARɣ) and 
CCAAT/enhancer-binding protein (CEBP)α, the two master regulators of adipogenesis. MiR-27a, has 
also been shown to inhibit adipogenic differentiation of 3T3-L1 preadipocytes (Lin et al., 2009). In 
animal models, mature adipocytes from obese mice had lower miR-27a expression as compared to lean 
mice, indicating miR-27a downregulation may be necessary for adipocyte hypertrophy (Kim et al., 
2010). The regulatory activity of miR-27a in relation to adipogenesis and obesity in PE and HIV 
infection, is however complex and warrants expansive investigation. 
Interestingly, adipose tissue is considered to be hormonally active, producing cytokines (Briana and 
Malamitsi-Puchner, 2009) that demonstrate the association of obesity with increased inflammation, 
insulin resistance and oxidative stress (Berg and Scherer, 2005, Greenberg and Obin, 2006). 
Inflammatory cytokine release from adipose tissue and elevated inflammatory cytokine levels including 
TNF-α and IL-6 have been associated with obesity (Cummings and Schwartz, 2003). The investigation  
of cytokines in relation to obesity was not the focus of the study, however, the  study did not find 
significant differences with IL-2, IL-4, IL6, IL-10, IL17a, TNF-α, and IFN-ɣ  concentrations in relation 
to rs895819 T>C polymorphism between the groups.  
 
Obesity is a major epidemic in developed countries, and the trend is now extending to developing 
countries (Misra and Khurana, 2008).The prevalence of obese and overweight women (BMI ≥25 kg/m2)  
in South Africa is estimated to be 69% by the (WHO, 2010). Although the  relationship of obesity to 
increase Type 2 diabetes and cardiovascular disease is well recognized, evidence suggests a three-fold 
increase in the risk of PE associated with obesity (Bodnar et al., 2005). In the United States, it appears 
that obesity is the leading attributable risk for PE (Bodnar et al., 2005), and in several other populations 
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around the world the relationship of obesity and increased risk of PE has also been reported (Mahomed 
et al., 1998, Hossain et al., 2007, Hauger et al., 2008). Interestingly, increases in BMI in the normal 
range has also been shown to be associated with an increased risk of PE (Bodnar et al., 2005). 
 
The clinical relevance of this study relates to the prevalence of obesity in South Africa, particularly 
among women and young girls (Hauger et al., 2008, Labadarios et al., 2005) which is progressively 
increasing (Labadarios et al., 2005, Senekal et al., 2003), however the study is limited by a small sample 
size, and racial and gender bias which require future large scale population based studies. The exclusion 
of a HAART naïve group limits comparisons on its effects, however the inclusion of such a group is 
unethical in current practice. The promotion of weight loss activities in pregnancy is not feasible, 
therefore effective obesity prevention strategies are needed which incorporate healthy diet and life style 
messages to  those who are at risk for HIV infection and other non-communicable diseases (Wand and 
Ramjee, 2013) to reduce morbidity and mortality.  
 
Taken together, the study provides an insight into the association of miR-27a and obesity and the 
association of miR-27a rs895819 polymorphism in relation to BMI, PE and the influence of HIV 
infection and HAART in pregnant women. Further scientific investigation is required in the long term 




MiR-27a has an important regulatory function in the development of obesity.  The functional 
rs895819 SNP may negatively regulate the adipogenic activity of miR-27a, and possibly increase the 
susceptibility to obesity in preeclamptic Black South African women on HAART. The data provides 
new insight into the role of miR-27a polymorphism in the triad of PE, HIV/HAART and obesity, and 
has potentially important future therapeutic implications.  
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Synopsis: MiR-146a GC/CC genotype may reduce susceptibility to severe preeclampsia, which may 
be   further influenced by the presence of co-morbid Human Immunodeficiency virus (HIV) infection 
















We investigated the association of the reference and variant genotypes of miR-146a rs2910164 G>C 
polymorphism in association with preeclampsia (PE), related features and cytokines and include a 
further analysis among preeclamptic women with HIV infection on HAART. 
 
Study Design: 
This hospital-based, case-control study was conducted by genotyping Black South African women, 
where the risk of both PE and HIV is high. Sixty women with PE and eighty normotensive women were 
genotyped by PCR-RFLP.  Serum cytokine levels (Th1 related cytokines) and (Th2 related cytokines) 
were also determined in 4 groups of pregnant women, viz : normotensive, HIV infected, preeclamptic 
and HIV infected preeclamptic women, using a Cytometric Bead Array assay.  
 
Results: 
There was no significant association of miR-146a polymorphism with PE susceptibility in our data. 
However, in the subgroup analyses, the variant genotypes (GC/CC) were significantly associated with 
lower severe PE risk (OR: 0.34, 0.12-0.99; p=0.048), more especially in the presence of HIV and 
HAART (OR: 0.11; 0.02-0.68, p= 0.018).  
 
Conclusions: 
Our study suggests that miR-146a rs2910164 polymorphism might not be associated with PE 
susceptibility, cytokines or related features. However, the miR-146a GC/CC genotype might reduce 
susceptibility to severe PE, which might be further influenced by the presence of co-morbid HIV 
infection among pregnant women on HAART.  
 







Preeclampsia and HIV infection contribute significantly to adverse maternal and perinatal outcomes 
globally (Backes, Markham et al. 2011),(Calvert and Ronsmans 2013) .   In South Africa, and other 
developing countries, the prevalence of both conditions remains high and these co-morbidities are 
important causes of mortality (Moodley and Kalane 2006),(Nel, Mabude et al. 2012), (Gebhardt, 
Fawcus et al. 2015). Despite extensive research, the pathophysiology of HIV infection and preeclampsia 
is not completely understood.  
 
Preeclampsia is heterogeneous in nature, and is associated with differences in the timing of disease, 
clinical manifestations, severity of organ damage, maternal and fetal outcomes and complications. The 
diverse nature of  preeclampsia is further evident in the severity in which it can manifest i.e. mild and 
severe disease (Sibai, Dekker et al. 2005). Although the definition of severe preeclampsia varies, it is 
generally associated inter alia with markedly elevated blood pressure, maternal neurological 
complications, seizures, signs of hepatic and renal dysfunction, and fetal affectation (Obstetricians and 
Gynecologists 2013). In the developing countries, severe forms of preeclampsia and eclampsia are more 
common, and range from a low of 4% of all deliveries to 18% in parts of Africa (Villar, Say et al. 2003). 
 
Preeclampsia is associated with a pro-inflammatory milieu, in which cytokines play a significant role 
as mediators (Raghupathy 2013). Other pathogenic mechanisms such as immune maladaptation, 
inadequate placental development and trophoblast invasion, placental ischaemia, oxidative stress and 
thrombosis are all thought to represent key factors in the development of preeclampsia (Williams and 
Pipkin 2011).  All of these components have genetic factors that may be involved in the pathogenesis 
(Williams and Pipkin 2011), which may alter susceptibility to preeclampsia or its complications. The 
genetic basis of preeclampsia is further supported by epidemiological findings that show a 2- 5 fold 
increased risk of pre-eclampsia in women with a maternal history of this disease.  (Uzan, Carbonnel et 
al. 2011). 
 
MicroRNAs (miRNAs) are small (+- 22 nucleotides), endogenous, non-coding RNA’s that regulate 
gene expression by modulating the expression of multiple target mRNA’s, inducing either translational 
inhibition or mRNA degradation (Li, Du et al. 2015). They are involved in various pathological (Li, Du 
et al. 2015) processes, including the regulation of innate and adaptive immune responses (Saba, 
Sorensen et al. 2014).  MiRNA-146a, is involved in modulating the negative regulation of Toll like 
receptor (TLR) signalling, and inflammatory cytokines. (Hill, Clement et al. 2015). MiRNA146a lies 
at the crossroads of biological processes that involve innate-immune responses, viral-infection and 
inflammatory disease (Hill, Clement et al. 2015). It   prevents an overstimulation of the inflammatory 
response through its recognised target genes, IRAK1 and TRAF6 (Hébert and De Strooper 2007), (Saba, 
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Sorensen et al. 2014), and its dysregulation is associated with many inflammatory diseases including 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (Li, Du et al. 2015) . Its role in 
preeclampsia has not been established.  
 
Polymorphisms may affect miRNA expression, maturation or mRNA recognition, and alter  disease 
susceptibility (Li, Du et al. 2015). MiRNA 146a has been  associated with the  single nucleotide 
polymorphism (SNP)  rs 2910164 G>C , which is located within the seed sequence of pre-miRNA 146a 
, which is the miRNA 146a precursor (Mehanna, Ghattas et al. 2015) ,(Kogo, Mimori et al. 2011). This 
functional polymorphism has been associated with various inflammatory diseases including rheumatoid 
arthritis and SLE. (Yang, Schlehe et al. 2010), (Löfgren, Frostegård et al. 2012) 
Based on  (1) the inflammatory milieu in preeclampsia and HIV, (2) the regulatory role of miR-146a in 
inflammatory responses, and (3) the association of miRNA 146a SNP rs 2910164 G>C polymorphism 
with inflammatory diseases, this study investigated the role of  rs2910164 with  preeclampsia risk , 
related features and associated cytokines . Due to the high prevalence of HIV  (Nel, Mabude et al. 2012), 
we included women with HIV infection on HAART in order to identify  a possible differential influence. 
To the best of our knowledge, this is the first study to investigate this association in high risk Black 
South African women during pregnancy.   
 
2. Materials and Methods: 
2.1. Study population and sample collection 
Institutional ethical and hospital regulatory permission was obtained for the study (Biomedical Research 
Ethics Committee, University of KwaZulu-Natal, South Africa; reference number BE 119/11). After 
informed consent was obtained, participants were recruited over a 14 month period  from July 2013 to 
September 2014 at the maternity unit at Prince Mshiyeni Memorial Hospital in Durban, South Africa. 
This hospital is a regional level facility and serves a predominantly semi –urban African population.  
Normotensive [n=95, (80 genotyped) age range: 16-46 years] and preeclamptic patients [n= 98, (60 
genotyped) age range: 16-42 years] were enrolled overall into the study. To maintain ethnographic and 
anthropometric consistency, all patients recruited were of African descent, resident in the same 
geographical location and of Zulu ethnicity. All patients were non-smokers, non-consumers of alcohol 
or recreational drugs, and all HIV infected patients were on HAART (tenofovir, emtricitabine, 
efavirenz) as per the National guidelines (Southern African 2013). Calcium supplementation was 
administered routinely to all patients attending the clinic. Women with gestational hypertension, renal 
disease, diabetes mellitus, chronic hypertension and collagen vascular disease were excluded. 
Preeclampsia was defined as a blood pressure ≥ 140mmHg systolic or ≥ to 90 mmHg diastolic on 2 
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occasions at least 4 hours apart after 20 weeks of gestation in a woman with previously normal blood 
pressure, consistent with guidelines (Obstetricians and Gynecologists 2013). All patients had 
proteinuria ≥ +1 on urine dipstick testing. Data on all patients was obtained from the institution’s 
maternity case records and laboratory data from the National Health Laboratory Services® computerised 
database at the institution. HIV was diagnosed on a rapid test kit and weight was categorised as: normal 
weight (BMI: 18-<25), overweight (BMI: 25-<30), obese (BMI: 30+). Early onset preeclampsia was 
considered as ≤ 34 weeks of gestation (Tranquilli , 2014). Severe preeclaampsia was diagnosed when 
features included any of the following: systolic blood pressure ≥160 mmHg or diastolic blood pressure 
≥110 mmHg; maternal neurological disorders such as persistent headaches and brisk reflexes, 
eclampsia, acute pulmonary edema, proteinuria ≥5 g/day, oliguria <500 cc/day, creatinine >120 μmol/L, 
features HELLP syndrome and thrombocytopenia <100,000/mm3, fetal criteria including intrauterine 
growth retardation, oligohydramnios, or fetal death in utero. (Obstetricians and Gynecologists 2013), 
(Sibai, Dekker et al. 2005) .    
 
2.2. Cytokine quantification: 
 
The BD Cytometric Bead Array Human Th1/Th2/Th17 Cytokine kit was used to measure Interleukin 
(IL) -2, IL-4, IL-6, IL-10, IL17a and Tumor Necrosis Factor (TNF-α) protein levels in a serum samples. 
Briefly, lyophilized standards were prepared by reconstitution and serial dilution (1:2 – 1:256) in assay 
diluent immediately before staining with Capture Beads and PE Detection Reagent. All serum samples 
were also diluted in assay diluent (1:4) before staining with Capture Beads and PE Detection Reagent. 
For the staining procedure, 50 μL of each standard and unknown sample was added to appropriately 
labelled sample tubes followed by 50 μL of the Human Th1/Th2/Th17 PE Detection Reagent and 
incubated (3 h, RT, protected from light). Following incubation 1 mL of Wash Buffer was added to 
each assay tube and centrifuged at 200g for 5 minutes. The supernatant from each assay tube was then 
carefully aspirated and 300 μL of Wash Buffer was added to each assay tube to resuspend the bead 
pellet. Flow cytometric data was acquired using the BD AccuriC6 Sampler counting 2100 gated events. 
This ensures that the sample file contains approximately 300 events per Capture Bead. Data analysis 
was performed using the FCAP Array analysis software.  
 
 
2.3. Genomic DNA extraction  
 
Genomic DNA was extracted from whole blood samples of the study subjects (80 normotensive and 60 
PE).  Cells were transferred to 600μL lysis buffer (0.5% SDS, 150mM NaCl, 10mM EDTA, 10mM 
Tris-HCl (pH 8.0)).  To this, RNase A (100μg/mL; DNase free) was added to the solution and incubated 
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(37oC, 1h).  Proteinase K (200μg/mL) was then added and incubated (50oC, 3h). Protein contaminants 
were then precipitated by adding 5mM 0.1% potassium acetate before centrifugation (5,000xg; 15min).  
Supernatants containing genomic DNA were transferred to fresh tubes and extracted with 100% 
isopropanol on ice, and thereafter washed with 70% ethanol.  DNA samples were dissolved in 10mM 
Tris and 0.1mM EDTA (pH 7.4, 4oC).  DNA concentration was determined using the Nanodrop2000 
spectrophotometer, and all samples were standardised to a concentration of 10ng/μL. 
 
2.4. Genotyping 
An optimised PCR was used to obtain the highest specificity and yield of the 147bp PCR product. This 
was achieved by amplification of the genomic DNA using 40pmol of each primer (Forward Primer: 50 
– CATGGGTTGTGTCAGTGTCAGAGCT – 30; Reverse Primer: 50 -
TGCCTTCTGTCTCCAGTCTTCCAA-30). A no-template sample was run with the positive samples 
as a quality control measure against PCR contamination. The 30μL reaction consisted of 200mM of 
each dNTP, 2.5mM MgCl2, 19 Green GoTaq Flexi buffer, 0.2U Go-Taq DNA polymerase (Promega) 
and 30ng genomic DNA template.  PCR was performed under the following cycling conditions: 94oC 
for 10min (initial denaturation), followed by 30 cycles of 94oC for 30s, 65oC for 30s (annealing) and 
72oC for 7min (final extension). PCR products were electrophoresed on agarose gel (1.8 %) and 
visualised using the Uvitech image documentation system (Uvitech Alliance 2.7).   
PCR–RFLP was used to determine the miR-146a rs2910164 genotypes. 15μL of each PCR product was 
subjected to restriction by 1.5μL (10u/μL) Sac I and 2μL 10x Buffer-Sac I (Fermentas). Overnight 
restriction occurred at 37oC, and thereafter restriction products were electrophoresed on agarose gel 
(3%) and visualised as was the PCR product. Presence of the wild-type G-allele resulted in no cleavage 
of the PCR product. The variant C-allele yielded two fragments of 122 and 25bp. The homozygous 
genotype yielded three bands of 147, 122 and 25 bp. Restriction products were run alongside a DNA 
ladder for accurate reading of fragment sizes, thus enabling correct analysis of genotypes. 
 
2.3. Statistical analysis  
Statistical analysis was done using SPSS® version 22. Correlation between continuous variables was 
assessed using the Spearman rank correlation coefficient. Comparisons of mean across 3 or more groups 
were done using the Kruskal– Wallis test. The Pearson Chi-square (χ2) test was used to test association 
between group(s) and categorical explanatory variables.  The Hardy–Weinberg equilibrium was used 
to test for deviation of allele/genotype frequency. Allele and genotype frequencies were calculated using 
the Fisher’s exact and Chi square tests, respectively. Other calculations were done using a one-way 
ANOVA. In the determination of significance, a p-value < 0.05 was deemed statistically significant. 
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3. Results:  
The clinical characteristics of participants are shown in Table 5.1. The study cohort was divided into 4 
groups: (1) uninfected preeclamptic women (PEHIV-), (2) infected preeclamptic women (PEHIV+), (3) 
uninfected normotensive women ( Normo -) and (4) infected normotensive women ( Normo +) . All 
women were in the third trimester of pregnancy and the mean gestational age was 36.5 weeks of 
pregnancy. There was a significant difference in the parity across all groups (p=0.006) but not between 
the preeclamptic women (p=0.400). There was also a significant difference in age across the groups, 
however there was little or no correlation between cytokine levels.  The average duration of HAART 
was 16.6 and 14.5 weeks in the normotensive and preeclamptic group respectively, however this is not 
a precise duration of exposure. There were differences in the mode of delivery, however these were 
based on obstetric related indications. CD4 counts were not routinely performed on uninfected women.  
Table 5.1: Clinical characteristics of participants 
Variable      PE HIV-  
( Grp 1 ) 








( Grp 3) 
( n=50) 
Normo + 
    (Grp 4) 







p value  
(Grp 1 vs 2) 
Age) (n, %)            















28 ± 6.4 
17-46 
192(99) 0.002 0.003 
Parity  
(n, %  )  




























   4 (100) 
0.006 
 





















 0.399* --- 



































































Abbreviations: GA = gestational age, BMI = Body Mass Index, MOD= mode of delivery, ELCS= elective 
caesarean section, EMCS= emergency caesarean section, NVD= normal vaginal delivery, SD=standard 




The genotype and allele frequencies of the ancestral / reference GG, heterozygous GC and homozygous 
CC variants are shown in Table 5.2 .There were no significant differences in the GC genotype (p= 
0.589), CC genotype (p=0.491) or G /C allele frequencies (p= 0.671) when compared between all 
preeclamptic and all normotensive women.  The genotype distribution was compatible with the Hardy 
–Weinberg equilibrium in the study sample (p=0.905; p=0.197). 
 
 
Table 5.2: miR-146a genotype and allele frequency distribution in controls and pre- eclamptic 
patients 
                  
 † Controls:  
(n = 80 ) 
‡ Pre-eclamptic  
(n =60 ) 
p-value (Odds 
ratio; 95% CI) 
Genotypes n (%)    
GG  31 (38.8) 24 (40.0) 1 (ref) 
GC  38 (47.5) 24 (40.0) 0.589 (0.82; 0.34-
1.71) 
CC  11 (13.8) 12 (20.0) 0.491 (1.41; 0.53-
3.74) 
Alleles n (%)    
G 100 (62.5) 72 (60.0) 0.671 (1.11; 0.66-   
1.86) C 60 (37.5) 48 (40.0) 
HWE p-value 0.905 0.197 0.439 
Abbreviations: HWE = Hardy Weinburg Equilibrium; CI =confidence interval; †= all normotensives; ‡=all 
preeclamptics; p<0.05 is statistically significant; n= cases genotypes G=guanine, C=cytosine,  
 
 
Table 5.3 represents a sub-analysis of the genotype and allele frequencies among women stratified 
according to HIV status (i.e. negative or positive).  No significant differences were noted in the 















Table 5.3: Genotype and allele frequencies between groups 
 NORMO HIV- 
 (n =42) 
NORMO HIV+  
(n =38) 
PE HIV-  
(n =31) 
PE HIV+  
(n =29) 
Genotypes n (%)     
GG 17 (40.5) 14 (36.8) 13 (41.9) 11 (37.9) 
GC 20 (47.6) 18 (47.4) 12 (38.7) 12 (41.4) 
CC  5 (11.9)  6 (15.8)  6 (19.4)  6 (20.7) 
Alleles n (%)     
G 54 (64.3) 46 (60.5) 38 (61.3) 34 (58.6) 
C 30 (35.7) 30 (39.5) 24 (38.7) 24 (41.4) 
HWE 0.810   0.957 0.305 0.428 
  
Group comparison:           Genotypes                                                  Alleles (G/C) 
   p-values (OR; CI)                                       p-values (OR; CI)                       
Norm - vs Norm + 
  GG 
  GC 
  CC 
 
1 (ref)                                                          1(ref) 
0.855 (1.09; 0.42-   2.83)                            0.624 (1.17; 0.59-  2.34) 
0.593 (1.46; 0.37-    5.80)                                                                                                                                         
Norm - vs PE HIV- 
  GG 
  GC 
  CC 
 
1 (ref)                                                         1 (ref) 
0.640 (0.78;  0.28-2.17)                             0.711 (1.14; 0.54-     2.36) 
0.525 (1.57; 0.39- 6.30) 
Norm + vs PE 
HIV+  
  GG 
  GC 
  CC 
 
1 (ref)                                                        1 (ref) 
0.765 (0.85; 0.29-    2.49)                          0.824 (1.08; 0.51- 2.30))                                                                    
0.732 (1.27;  0.32-5.06) 
                      
Abbreviations: PE= preeclampsia; norm+ normotensive; HWE= Hardy Weinburg Equilibrium; p<0.05 is 
statistically significant; n= genotyped cases GG = reference genotype   G= reference allele  
 
 
Table 5.4 represents the odds ratios (OR) and p values for the cytokines and selected features associated 
with preeclampsia. There were no significance differences noted with any of the mean cytokine levels 
or the other variables assessed in the groups, except for severe preeclampsia, where a significant 
difference was noted across the genotype groups.( p= 0.048) . In a further sub-analysis according to 
HIV infection, the odds ratio for severe preeclampsia was significantly lower for the genotypes in the 
HIV + group (p=0.018). Taken together, the OR for severe preeclampsia was lower among the GC/CC 
genotypes compared with the ancestral genotype GG in all preeclamptic women (OR: 0.34 (0.12 -0.99) 
(p=0.048) and even lower in HIV infected preeclamptic women with the GC/CC genotypes (OR: 0.11; 






Table 5.4: Odds ratios for variables in all preeclamptic women and according to HIV status. 
Variable   N 
 60 
      GC/CC  vs  GG (ref) 
        (n=36)      (n=24) 
 
              OR (95%, CI) p-value 
BMI   46 0.98 (0.9-1.06) 0.612 
Age   60 0.98 (0.91-1.06) 0.569 
CD4   30 1 (0.99-1.0) 0.135 
EOPE   60 0.79 (0.27-2.28) 0.665 
Severe Preeclampsia   60 0.34 (0.12-0.99) 0.048* 
No of AHT drugs   60 1.1  (0.69 -1.7)                                          0.676 
SYS BP   59 1.01( 0.99-1.03)                                   0.263                          
DIA BP   59 1.01 (0.98-1.04)                                       0.421                            
IL2   17 0.96 (0.9-1.02) 0.199 
TNF-α  18 1 (0.98-1.02) 0.907 
IL-17α  17 1 (1.0-1.0) 0.642 
IL-6  18 1 (0.99-1.01) 0.976 
IL-10  17 1 (1-1.01) 0.658 
IL-4  18 1.01 (0.98-1.04) 0.582 
 
                                 GC/CC  vs  GG 
PE HIV –(n=31) 
OR(95% CI)  
p value GC/CC  vs  GG  
PE HIV+ (n= 29) 
OR(95% CI)  
p value 
Severe PE 0.74 (0.18-3.15) 0.686 0.11 (0.02-0.68)   0.018* 
     
Cytokines   
IL2 0.96 (0.88-1.04) 0.271 0.95 (0.89-1.02) 0.165 
TNFα 0.89 (0.72-1.09) 0.250 0.99 (0.89-1.1) 0.873 
IL17a 0.99 (0.96-1.02) 0.444 1 (1.0-1.0) 0.88 
IL6 1.01 (0.99-1.02) 0.392 1 (1.0-1.0) 0.327 
IL10 1.01 (0.99-1.02) 0.464 0.94 (0.83-1.06) 0.286 
IL4 1.0 (1-1.01) 0.351 0.94 (0.86-1.03) 0.202 
Abbreviations: OR= odds ratio, BMI =body mass index (kg/m2), EOPE= early onset preeclampsia, AHT = 
antihypertensive drugs, SYS= systolic, DIA= diastolic, BP= blood pressure (mmHg), IL+ interleukin, 








The dysregulation of miRNA146a has been associated with inflammatory diseases such as rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE) (Yang, Chen et al. 2012) ,(Löfgren, Frostegård 
et al. 2012). A downregulation of  miRNA 146a has been found in placentas of preeclamptic women 
compared with normal women (Chen and Wang 2013), therefore suggesting a potential role  for 
miRNA146a in the pathogenesis of preeclampsia. Based on the presence of an  increased inflammatory 
environment in preeclampsia  (Murphy, Tayade et al. 2015), (Garovic and August 2013), (Ramma and 
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Ahmed 2011), polymorphisms in the miRNA146a gene may therefore affect susceptibility to 
preeclampsia. The rs 2910164 G>C polymorphism of miRNA146a has recently been studied in 
inflammatory conditions (Yang, Chen et al. 2012), however its role in preeclampsia and co-morbid HIV 
infection has not been evaluated.  
 
Inflammation is mediated by a variety of soluble factors, including cytokines (Shaikh, Sharma et al. 
2011), which were evaluated in this study.  Preeclampsia  is characterised by significantly higher levels 
of pro-inflammatory cytokines such as  IL-6 and TNF-α, when compared with normal pregnant women 
(Catarino, Santos-Silva et al. 2012). In  HIV infection ,  the move away from  a   pro-inflammatory 
cytokine milieu that occurs as disease progresses, is counteracted with the usage of HAART (Fiore, 
Newell et al. 2006). 
Our data did not show any significant association in the frequency of the variant genotypes (GC/CC) in 
women with preeclampsia and there was no significant association in the groups stratified according to 
HIV.  Furthermore, we did not find a significant relationship of the variant genotypes with cytokines or 
the features of preeclampsia that were assessed when stratified according to HIV status.  However the 
odds ratio (OR) for the presence of severe disease was significant (GC/CC) (0.34: 0.12-0.99; p=0.048), 
suggesting a reduced susceptibility for the development of severe disease with the variant genotype. 
The OR for severe preeclampsia was also significantly lower among HIV infected preeclamptic women 
with the GC/CC genotypes. (0.11; 0.02-0.68, p= 0.018), suggesting a differential dysregulation in the 
presence of HIV infection.  
  
Severe PE is associated with adverse neonatal outcomes, is more likely to recur (Rey and Couturier 
1994) ,   and is also associated with increased maternal morbidity. (Sibai, Mercer et al. 1991). Moreover, 
women   with severe PE are at high risk for cardiovascular disease later in life. (Smith, Pell et al. 2001) . 
Eclamptic seizures, intracerebral haemorrhage, pulmonary oedema or heart failure, acute renal failure, liver 
dysfunction, and coagulation abnormalities are all associated with severe pre-eclampsia. (Rudra, Basak 
et al. 2011). Fetal complications include intrauterine growth restriction, premature delivery, and 
intrauterine fetal death (Rudra, Basak et al. 2011). Eclampsia, a severe form of preeclampsia 
characterised by seizures, is associated  with a (0%-1.8%) mortality rate in  developed countries rising 
to  a high rate of 15% in developing countries (Ghulmiyyah and Sibai 2012). Furthermore, obesity is a 
known risk factor for preeclampsia  (Stone, Lockwood et al. 1994) , a finding relevant to our study  ( 
mean BMI among the HIV infected preeclamptic women was 39.4 kg/m2 ).  
 
The role of miRNA 146a in HIV infection has emerged more recently. Spinello et al. (2011) reported a 
relationship between miR146a and CXCR4 co-receptor in HIV (Spinello, Quaranta et al. 2011). Resting 
CD4+T cells have high expression of miR-146a, which inhibits the expression of the co-receptor 
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CXCR4, and prevents the HIV entry in CD4+T cells (Spinello, Quaranta et al. 2011), (Quaranta, 
Olivetta et al. 2015). Furthermore, Duskova et al. (2013)   demonstrated that miR-146a was significantly 
increased in infected patients as compared to healthy controls. (Duskova, Nagilla et al. 2013).  
 
Our study demonstrates the relationship of miR-146a rs2910164 G>C polymorphism with 
preeclampsia, some of the related features, cytokines and HIV/HAART. Of note is the increased 
susceptibility to severe disease in local women with the ancestral genotype. However, our findings are 
preliminary and limited by small sample sizes. Further, the influence of other functional polymorphisms 





MiR-146a rs2910164 G>C polymorphism might not be associated with PE susceptibility, cytokines or 
related features. However, the miR-146a GC/CC variant genotypes might reduce susceptibility to severe 
PE, which might be further influenced by the presence of co-morbid HIV infection among pregnant 
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Preeclampsia (PE) and HIV/AIDS contribute significantly to morbidity and mortality worldwide, more 
especially in poorly resourced countries (Backes, Markham et al. 2011), (Calvert and Ronsmans 
2013),(Duley 2009).  Whilst the treatment of PE remains empiric, HAART is used in the management 
of HIV infection both for maternal health and for the prevention of vertical transmission during 
pregnancy. In South Africa, an upper middle income developing country, PE and HIV/AIDS remain 
among the leading causes of maternal mortality, and have become a National health priority.   (Moodley, 
Pattinson et al. 2014), (Gebhardt, Fawcus et al. 2015). Moreover ,South Africa has the added challenge 
of a high prevalence of both these conditions (Moodley and Kalane 2006),(Nel, Mabude et al. 2012).  
 
The exact relationship between PE and HIV remains controversial and consensus is lacking on the 
clinical and scientific impact of HIV/HAAART  on PE (Kalumba, Moodley et al. 2013), (Frank, 
Buchmann et al. 2004), (Mattar, Amed et al. 2004) ,(Cassidy-Matthews 2015). Furthermore, the 
pathophysiology HIV/AIDS, and PE is not completely understood, despite extensive research. 
Contemporary studies acknowledge the role of  immunological and inflammatory pathways, involving 
mediators such as cytokines (Shaikh, Sharma et al. 2011), as well as  genetic pathways (Williams and 













Figure 6.1. Outline of the 4 areas of investigation in this study  
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In line with  the United Nations Millennium Development Goals (MDG’s) (Bhutta, Chopra et al. 
2010)  to formulate effective care and improve outcomes, further clinical and scientific research of 
these conditions is necessary to improve our understanding and guide effective care. 
 
In this study, we investigated four areas relating to the pathophysiology of PE and HIV/HAART viz. 
clinical, biochemical, immunological and genetic/ epigenetic aspects as shown in Figure 6.1. Our 
findings show that in preeclampsia, HIV / HAART is not associated with significant differences in the 
biochemical indices, clinical features or maternal and fetal adverse outcomes compared with uninfected 
preeclamptic women. However, we found a significant difference in gamma glutamyl transferase, a 
hepatic enzyme, in preeclamptic HIV infected women on HAART compared with uninfected women 
with preeclampsia. Because HIV has immune depressive effects, an association between HIV and 
preeclampsia has been suggested (Hall, Gebhardt et al. 2014). The postulated inhibitory effect of HIV 
on preeclampsia may be potentially reconstituted by HAART, which may explain the absence of 
significant differences in many of the clinical and biochemical sequelae when compared with uninfected 
preeclamptic women. The  liver, which is a target organ both in preeclampsia and for the side effects of 
HAART (Obstetricians and Gynecologists 2013), (Browne, Schrier et al. 2015) may endure a dual 
impact , as suggested by the findings of a significant increase in gamma glutamyl transferase (GGT) 
between the groups.   
 
Our findings also show that in uncomplicated/normotensive pregnancies, HAART is associated with 
significant decreases in IL-2, TNF-α and IL-6, and in preeclamptic women, it is associated with 
significant decreases in IL-2 and TNF-α, compared with uninfected women. These findings suggest that 
HIV/HAART impacts on pro-inflammatory cytokines in women with preeclampsia and provides a 
platform for further research on the immune reconstitution effects of HAART during pregnancy, and 
the development of potential immune modulation therapies for the management of preeclampsia. These 
findings may correlate with  clinical data however further studies are necessary.(Mattar, Amed et al. 
2004) (Hall, Gebhardt et al. 2014),  
 
In determining the role of genetic polymorphisms and susceptibility to preeclampsia and some of the 
risk factors, single nucleotide polymorphisms (SNP) miRNA 27a rs 895819T>C and miRNA 146a rs 
2910164 G>C,  were   investigated  due to their association with  biological processes implicated in PE. 
We did not find increased susceptibility to PE with variants TC/C and GC/CC, however the data show 
significant associations with obesity and severe disease respectively which are further dysregulated in 
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the presence of HIV/ HAART. Further large explorative studies on heterogeneous populations are 
necessary, however the findings provide an insight into the genetic/ epigenetic mechanisms that may 






 The benefits of HAART for maternal health and prevention of mother to child transmission 
outweigh the potential clinical and biochemical risks associated with it in women with PE and 
continued advocacy for its usage is necessary.  
 Serial monitoring of Liver Function Tests are necessary in women with PE and HIV/HAART, 
to detect liver dysfunction early and prevent morbidity and mortality. 
 The maternal records should include detailed information on HAART usage to assess its 
effects more accurately.  
 Strategies to prevent obesity, which is likely to further complicate the long term cardiovascular 




 The unifying link between immunological factors and features of the maternal syndrome in 
preeclampsia remains unclear and requires ongoing investigation. 
 The role of the placenta in preeclampsia and HIV is not fully understood, and investigation of 
placental immunogenic factors and epigenetic factors requires further evaluation. 
 Studies on preconceptual immune priming and maternal tolerisation to paternal antigenic 
material, are necessary to help us further understand the immunogenic basis of preeclampsia.  
 Studies on racial variation and genetic susceptibility to preeclampsia may help us explain the 






6.3. Concluding statement: 
In the final analysis, it is evident that the intriguing and elusive nature of preeclampsia still prevails, 
and co-morbid HIV infection and HAART may have differential effects on certain aspects of the 
disease. PE is heterogeneous in nature and the aetiology is complex and likely to be multifactorial, 
extending beyond a singular pathophysiological mechanism. The next decade presents an opportunity 
to conduct further studies on the molecular and genetic aspects of preeclampsia, and perhaps thereafter, 
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